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ZUSAMMENFASSUNG 
 
Metastasierung ist ein sehr häufiger Prozess bei Krebserkrankungen und das 
entscheidende Kriterium für durch Krebs verursachte Todesfälle. Metastasierende 
Tumorzellen wandern aktiv im Gewebe, gehen ins Blut/Lymphe und werden 
invasiv, d.h. wandern in entfernte Organe aus, wo sie Tochtergeschwülste 
(Metastasen) bilden. Dies wird durch genomische Veränderungen, die 
Tumormikroumgebung mit erhöhter Protease-Aktivität und modifiziertem ECM und 
Stroma unterstützt. Infolgedessen brechen die Zellen durch Gewebebarrieren und 
Basalmembranen und es werden sekundäre Tumore in entfernten Organen gebildet. 
Bei den ersten Schritten der frühen Metastasierung, bevor sich die Zellen aus dem 
primären Tumor lösen und sich verbreiten, tritt ein Prozess namens Epitheliale 
mesenchymale Transition (EMT) auf, bei dem die Zellen ihre epitheliale Polarität 
und Fähigkeit zur  Zellkontaktbildung verlieren. Sie weisen dann den Phänotyp von 
Bindegewebszellen (Fibroblasten) auf.  
 
EMT erfordert eine kooperative Wirkung von aktiviertem Ras und TGFß Signalling. 
Eine Studie über Expressionsanalyse, um EMT spezifische , durch TGFß induzierte 
Targetgene in einem epithelialen Maus- Brustkrebs- Zellmodell zu finden , hat ein 
neues, Zytokin ähnliches Protein namens ILEI (Interleukin like EMT-Inducer) 
identfiziert. TGFß reguliert ILEI auf der translationalen Ebene hoch. Dauerhafte 
Überexpression von ILEI in einigen Zelllinien verursacht EMT und verstärkt 
Tumorwachstum und Metastasierung. 
 
ILEI ist ein fakultativ sezerniertes Protein und seine sekretierte Form wird durch 
Serinproteasen wie Plasmin spezifisch an einer R / S Site am N-Terminus gespalten. 
Die physiologische Rolle der ILEI Spaltung in der Tumorgenese wurde bei 
tumorigenischen aber nicht metastatischen EpC40 Zellen, die verschiedene mutierte 
Formen des Proteins überexprimieren, analysiert. Das Protein wurde mutiert; 
entweder durch Einführung von Punktmutationen auf der Spaltstelle (cleavage 
mutant), welche das proteolytische Spalten durch Proteasen inhibieren, oder das 
Propeptid an dem N-Terminus wurde deletiert (∆-pro peptid mutant), was zu einem 
konstitutiv gespaltenen, reifen ILEI Protein führt. (bei dem Protease-Spaltung nicht 
mehr benötigt wird.) Das Fehlen des Propeptides am N-Terminus gewährleistet.eine 
hohe Sekretion des Proteins. In vivo Tumorigenese Experimente haben demonstriert, 
dass die cleavage Mutante überexprimierte EpC40 Zelle kleine Tumoren und sehr 
wenige Metastasen im Vergleich zu den wt-ILEI überexprimierten Zellen gebildet 
haben. Daneben beschleunigten die ∆-pro Peptid ILEI überexprimierten Zellen die 
Tumorentwicklung sogar stärker als die wt-ILEI überexprimierten Zellen und wiesen 
erhöhte Metastasierung auf. Wir untersuchten die Notwendigkeit der ILEI Spaltung 
für ein  verstärktes Tumorwachstum im Tumorigenese-Testen bei denen ein nicht 
spezifischer Proteaseninhibitor, Aprotinin verwendet wurde.  
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Wir erhielten eine signifikant verminderte Tumorwachstumsrate und Tumorgröße 
nur bei wt-ILEI überexprimierten Zellen im Vergleich zu den unbehandelten Tiere. 
Wie erwartet, hatte Aprotinin bei durch die ∆-pro peptid Mutante erzeugten, 
schnellwachsenden Tumoren keine Wirkung, da dieses Proteiun ja bereits gepalten 
ist. In vitro Experimente wießen darauf dass, die ILEI Sekretion durch exogenes 
Plasmin stimuliert werden kann.  
 
In weiteren Analysen zur Erklärung der Ursache dieses Phänomenes, wurde getestet, 
ob die ILEI-Sekretion durch die Aktivierung von Plasmin – uPAR Signalling reguliert 
werden könnte und nicht durch einen „autocrine Feed-back“ Mechanismus von ILEI, 
bei dem die gespaltene reife ILEI-Form seine eigene Sekretion ausgelöst haben 
könnte. 
 
Im zweiten Teil dieser Diplomarbeit wurde ein doxycyclin induzierbarer (TET-ON) 
ILEI transgenischer Mausstamm in vitro und in vivo auf die Induzierbarkeit und die 
Expressions-Stärke des durch das ILEI Transgen kodierte Protein bestimmt. Zwei 
Transgene, TetrTA und tetO-ILEI, wurden durch homologe Rekombination in 
spezifische Loci (ROSA26 and Col1A1) des Mausgenoms eingeführt, um 
Nebenwirkungen von zufälliger Integrationen, wie Zerstörung von endogenen 
Genen, zu vermeiden. 
 
Doxycyclin induzierte ILEI Expression wurde in allen untersuchten Geweben außer 
in der Lunge detektiert. Die höchsten Expression Levels wurden im Dünndarm und 
Dickdarm gefunden. Dieses induzierbare ILEI transgenische System ermöglicht das 
Studieren der physiologischen Funktion von ILEI und seiner Rolle in der 
Krebsentwicklung.  
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ABSTRACT 
 
Metastasis is the main reason for cancer related deaths. Epithelial tumor cells become 
invasive and motile, aided by genomic alterations and the tumor microenvironment 
with increased protease activity and modified ECM and stroma. As a result, the cells 
break down tissue barriers and establish secondary tumors at distant organs. During 
the early steps of metastasis, when tumor cells start to disseminate from the primary 
cancer, a process called epithelial to mesenchymal transition (EMT) occurs, in which 
cells loosen cell-cell contacts and deregulate their epithelial polarity.  
EMT requires a cooperative action of activated Ras and TGF signaling. Expression 
profiling studies to identify TGF-induced, EMT specific target genes in a murine 
mammary epithelial cell model has revealed a novel cytokine like protein, named 
ILEI (interleukin like EMT inducer). TGF upregulates ILEI at the translational level. 
Stable overexpression of ILEI in several cell lines caused EMT, elevated tumor 
growth and aspects of metastasis.  
ILEI is a secreted protein and its secreted form is cleaved by serine-type proteases, 
like plasmin, specifically at an R/S site at its N terminus. The physiological role of 
ILEI processing in tumorigenesis was analyzed using tumorigenic but non-metastatic 
EpC40 cells overexpressing (OE) different mutant forms of the protein. The protein 
was mutated either by introducing point mutations at the cleavage site, which 
inhibited proteolytic cleavage by proteases, or the pro-peptide at the N-terminus was 
deleted, creating an artificially matured protein not requiring proteolytic cleavage. 
This lack of the pro-peptide at the N-terminus caused constitutive, abnormally high 
secretion of the protein. In vivo tumorigenesis experiments demonstrated that 
cleavage mutant overexpressing EpC40 cells formed small tumors and very few 
metastases compared to the wt-ILEI OE cells. In addition, ∆-pro peptide ILEI OE cells 
accelerated tumor development even more than the wt-ILEI OE cells and exhibited 
enhanced metastasis. We examined the necessity of ILEI cleavage for generating 
elevated tumor growth in tumorigenesis assay using a non-specific serine protease 
inhibitor, aprotinin. Mice treated with this inhibitor showed significantly decreased 
tumor growth rates and tumor sizes induced by wt-ILEI OE cells, as compared to 
animals not treated with inhibitor. In vitro assays indicated that ILEI secretion can be 
stimulated by exogenous plasmin. Further analyses in attempts to explain the cause 
of this phenomenon suggested that it might occur via the activation of plasmin - 
uPAR signaling, and not through an autocrine feedback mechanism of ILEI, where 
the processed form would trigger its own secretion.  
 
In the second part of this diploma thesis, a doxycyclin inducible (TET-ON) ILEI 
transgenic mouse strain was characterized in vitro and in vivo for the inducibility 
and expression levels of the ILEI transgene. The two transgenes, TetrTA and tetO-
ILEI were introduced into specific loci (ROSA26 and Col1A1) by homologous 
recombination, eliminating the side effects of random integration such as disruption 
of endogenous genes. Doxycyclin responsive ILEI expression was detected in all 
examined tissues except lung. Highest expression levels were found in small and 
large intestines. This inducible ILEI transgenic system allows studying the 
physiological role of ILEI and its role in cancer development.  
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PART I  
MECHANISM OF ILEI CLEAVAGE and ITS PHYSIOLOGICAL RELEVANCES  
 
1. INTRODUCTION 
 
1.1 Through a malignant cell towards death: Cancer in multistep processes 
 
Cancer is a major cause of mortality worldwide, leading around to 13% of all human 
deaths (WHO), despite improved therapeutic implications in the last five decades. 
The disease involves multiple steps, i.e various mutations alterations in the genome 
that cause the cells to become more and more malignant. Despite the highly diverse 
genetic changes that contribute to cancer, a common set of properties accounts for the 
generation of all types of human tumor cells. Indeed six acquired capabilities have 
been elucidated that are involved in this malignancy process. (a-f) (Weinberg, 
Hanahan 2002) (FIGURE 1) 
 
a) Self-sufficiency in growth signals: Tumor cells produce their own growth signals. 
This capability decreases the dependence on exogenous signals from their 
microenvironment. Tumor cells escape from homeostatic mechanisms, which control 
normal cellular behaviour in a tissue.  
 
b) Insensitivity to growth-inhibitory signals: Antigrowth signals can induce cellular 
quiescence (G0) and block active proliferation. Tumor cells must evade these 
cytostatic anti-growth signals using various strategies. Overexpression of c-myc 
oncoprotein or disruption of the pRb pathway disrupt the ability of cancer cells to 
undergo terminal differentiation. 
 
c) Evasion of apoptosis (programmed cell death): Cancer cells acquire resistance 
towards apoptosis by altering molecular players that contribute to apoptosis 
signalling.  
 
d) Limitless replicative potential: Beside independence on their environment and 
evading apoptosis, tumor cells must acquire unlimited replicative potential and 
circumvent cellular senescence. Normal cells have an intrinsic autonomous program 
of restricting proliferation after a fixed number of cell divisions, due to telomere 
shortening during consecutive divisions. Tumor cells evade also this limited 
proliferation capacity by maintaining telomere length through the constitutive 
upregulation of the telomerase enzyme. 
 
e) Sustained angiogenesis: Neovascularisation – i.e formation of new blood vessels – 
is important for cancer cells. It provides oxygen and nutrients and thus enables 
cancer cells to form larger tumors. Tumor cells induce formation of new blood 
vessels by activating various angiogenic signals such as growth factors such as 
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), 
cytokines or chemokines and counteracting inhibitors.  
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f) Invasion and metastasis: Tumor cells that have acquired all these five capabilities 
can disseminate from their primary tumor mass and invade surrounding tissues and 
blood vessels to establish new colonies at distant organs. The generation of epithelial 
tumors at secondary sites occurs in distinct steps and is called metastasis. During this 
process cells lose their epithelial polarity, gain anchorage independence and become 
invasive and motile. (FIGURE 2). In addition to other modifications, altered 
expression of extracellular proteases and surface molecules e.g. cadherins and 
integrins and changes in the tumor microenvironment give rise to this migratory 
phenotype, causing 90% of human cancer deaths. (Sporn MB, 1969) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1 | Hallmarks of cancer (Hanahan and Weinberg, 2002) 
Most cancers have acquired the same set of functional capabilities during their development, 
through various mechanistic strategies. 
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FIGURE 2 | Metastasis formation of epithelial derived cancer cells (Thiery JP. 2003) 
                    EMT: epithelial to mesenchymal transition causes possibly the first step of local  
                        dissemination of carcinomas. 
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1.2 EMT 
 
Two main cell types –epithelial and mesenchymal- were described on the basis of 
their shape and specialized membrane structures. Epithelial cells form monolayers, 
adhere to each other and to the extracellular matrix (ECM) by tight junctions, 
adherens junctions, desmosomes and gap junctions. Claudins and occludins are the 
major tight junction proteins, which maintain cell-cell interactions and join together 
the cytoskeletons of adjacent cells. Adherens junctions occur at cell-cell junctions and 
are composed of cadherins. Gap junctions built up by connexins directly connect the 
cytoplasms of two cells. Integrins are plasma membrane receptors for e.g. extracellu-
lar matrix proteins and the main players to mediate cell contact with surrounding 
tissues as well as with other cells or with the ECM. They can bind to and couple ECM 
components with the cytoskeleton of the cell. The organisation of these junctions in a 
basal plane, the distribution of the adherens and polarized organization of the actin  
cytoskeleton apical of the ECM are characterized as apico-basal polarity of epithelial 
cells, in which the movements of cells are limited to the two dimensional space and 
restricted by neighboring cells. On the contrary, mesenchymal cells form variable cell 
shapes with an anterior-posterior rather than apico-basal actin polarization. They 
interact with other cells only at focal adhesion sites and elongate with a leading edge 
enriched in integrins and matrix metalloproteinases (MMP). They are motile cells, 
indeed they can move in all three dimensions by actin reorganization. (Berx G. 2007) 
 
EMT –epithelial to mesenchymal transition- occurs when cells lose their epithelial 
characteristics and gain mesenchymal features. This is actually a reversible process 
since it has been reported that these cells can regain a fully differentiated epithelial 
phenotype via mesenchymal-to-epithelial transition (MET). However, EMT and MET 
involve distinct signalling pathways depending on the cell type. EMT is first revealed 
during embryological processes, as a key process in early development. For example, 
in vertebrates it is associated with the establishment of the three-layer stage by 
gastrulation and later in development with the formation of some organs and tissues. 
In the adult, EMT-like processes contribute also in wound healing and in diseases 
such as fibrosis and tumour metastasis (FIGURE 3; Thiery JP.; 2003, 2006) 
 
Epithelial and mesenchymal cells show large differences in the expression of specific 
markers. For example, E-cadherin, a transmembrane protein localized to the 
adherens junctions and basolateral membrane and organising cell-cell adhesion 
complexes is known as a typical marker of epithelial cells and usually 
downregulated during EMT. Another epithelial protein (zona occludens 1; ZO1) is 
expressed in tight junctions and interacts with components of tight junctions and also 
with the actin cytoskeleton.  On the other hand, mesenchymal cells express 
intermediate filaments, a well-known example is vimentin. It helps maintaining cell 
integrity as a cytoskeletal component with a dynamic structure and provides 
flexibility to the cell. ECM components such as fibronectin and collagen precursors 
are expressed in mesenchymal cells as well. (Thiery JP.,2006) 
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In the context of tumorigenesis, cells acquire a spindle-shaped, highly motile and 
invasive fibroblastoid structure during EMT. Additionally they change their gene 
expression pattern through specific signalling molecules, i.e activation of 
mesenchymal markers combined with repression of tight- and adherens junction 
proteins. Thus they are able to migrate away from the primary tumor and to traverse 
through the basement membrane into the circulation, constituting early steps of 
metastasis.  Loss of E-cadherin and gain of vimentin and ECM components are well-
accepted markers of EMT. (FIGURE 3; Thiery JP.;2003) 
 
Besides, at least five signalling pathways that are central players in early embryonic 
development also control EMT (WNT, TGF, Hedgehog, Notch and receptor tyrosine 
kinase (RTK)/Ras signalling pathways). In the context of cancer these pathways are 
generally disregulated, and drive cells towards EMT. (Gruenert S., 2003; Huber MA., 
2005; Berx G., 2007; Thiery JP. 2003; 2006) Moreover gene expression profiling studies 
uncovered numerous transcription factors (e.g. Snail and Twist as repressors of E-
cadherin) and signalling pathways (e.g. PDGF/R and NFB signalling) that 
contribute to EMT. (Yang, 2004; Huber, 2004; Jechlinger, 2006) 
 
 
 
FIGURE 3 |   The cycle of epithelial cell plasticity (Thiery JP. 2006) 
                             E-cadherin, epithelial cadherin; ECM, extracellular matrix; FGFR2, fibroblast-growth   
factor receptor-2; FSP1, fibroblast-specific protein-1; MFs, microfilaments. 
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1.3 The dual face of TGF signalling on tumorigenesis  
 
In mammals, the TGF family consists of three highly homologous genes encoding 
TGF-1,-2 and-3. They are secreted proteins and released to the ECM as latent 
growth factors, where they are activated by plasmin, matrix metalloproteinases or 
ECM proteins. Active TGF’s bind to heteromeric signalling receptors. There are two 
types of transmembrane receptor serine threonine kinases forming the TGF receptor 
complex: TGF Receptor II (TRII) functioning in ligand binding and TGF Receptor 
I (TRI), representing the signalling receptor component. Once TGf binds to the 
receptor complex, TRII phosphorylates TRI, which then signals through distinct 
pathways: the well described SMAD signalling pathway and other pathways 
involving the mitogen-activated protein kinases (MAPKs), phosphoinositol-3 kinase 
(PI3K), and PP2A/p70s6K (FIGURE 4). TGFs regulate diverse processes including 
cell proliferation, -development and -behaviour, wound healing, immune 
surveillance and angiogenesis. (Wakefield LM.,2001; Massague, 1998)  
 
 
 
 
 
FIGURE 4 | TGFβ signalling pathways (Wakefield LM. 2001) 
                      SBE, Smad-binding element; TBE, transcription factor binding element 
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In most epithelial cells, TGFinhibits cell proliferation through activation of SMAD 
protein complexes, which then lead to the upregulation of cyclin-dependent kinase 
inhibitors or to the repression of the c-myc promoter resulting in cell cycle arrest and 
often apoptosis. The ability to arrest cell growth identifies TGF as a potential tumor 
suppressor, this occurs, however, only during early stages of epithelial tumors. (Cui 
W., 1996; Derynck R., 2001). Interestingly, at later stages of tumor progression, almost 
all human carcinomas and carcinoma-derived cell lines overproduce TGF, since 
they have gained resistance to growth inhibition by TGF due to receptor mutations 
and defects in components of the TGF signalling machinery. (Akhurst RJ., 2001; 
Derynck R., 2001; Wakefield LM.,2001) Loss of growth inhibitory responses via 
diminished TRII activity facilitates oncogenic effects of TGF on the tumor cell and 
tumor stroma. (Oft M., 1996) Further, TGF1 increased the metastatic potential of 
mammary tumors. (Welch DR., 1990) During tumorigenesis, cells most probably 
overcome the tumor suppressive activities of TGF switching towards its pro-
oncogenic role and stimulating invasion, angiogenesis and metastasis of epithelial 
tumors (FIGURE 5). In breast cancer, the expression levels of TGF1 correlate 
positively with the disease state and metastatic potential. (Gorsch SM., 1992) Indeed, 
cell-autonomous TGF signalling via an autocrine loop is necessary for induction of 
in vitro invasiveness and support of metastasis at late stages of tumorigenesis. (Oft 
M., 1998) For skin carcinomas in mice the consequence of this cell autonomous TGF 
signalling is a  more aggressive spindle cell phenotype and invasive behaviour, 
which is sufficient to enhance malignancy and metastatic capability of tumors. 
(Portella G., 1998) TGF has been shown in normal and transformed breast epithelial 
cells to be involved in epithelial to mesenchymal transition (EMT). EMT requires the 
cooperation of MAPK- and SMAD signalling, which are both target pathways of 
TGFs. (Oft M., 1996)  
 
In summary, TGFs indirectly targeting the tumor stroma or directly affecting the 
tumor cell itself stimulate tumorigenesis as a result of its action in 
immunosuppression or in angiogenesis or of its direct affect in modulating cellular 
plasticity. (Derynck R. 2001) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5 |Alternative roles of TGFβ in tumorigenesis targeting the tumor cell.              
                      (Derynck R. 2001) 
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1.4 RAS signalling  
 
Ras proteins belong to a large family of small GTPases. There are three human ras 
genes, H-, N-, and K-ras. They associate with the inner face of plasma membrane 
where they mediate signalling through diverse extracellular stimuli transmitted to 
Ras via plasma membrane growth factor receptors and downstream signalling 
proteins. Ras activity relies on a switch mechanism between inactive GDP-bound and 
active GTP-bound protein conformations. GTP-bound Ras binds to and activate more 
than 10 different effector molecules that are characterized by their Ras binding 
domain. These effectors regulate complex signalling cascades, including cell 
proliferation, differentiation and survival The first discovered and best described Ras 
effector pathway is the Raf serin-threonin kinases-MEK-ERK cascade, and others Ral 
guanine nucleotide dissociation stimulator (RalGDS) and phosphatidylinositol 3-
kinase (PI3K).   (Rajalingam K., 2007, Schubbert S., 2007, Repasky GA., 2004)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 |   Ras upstream and downstream signalling Campbell PM., 2004 
 
 
Ras binds to and activates Raf, which in turn initiates a signalling cascade 
phosphorylating the MEK1 and MEK2 dual specificity kinases. These kinases then 
phosphorylate and activate ERK1 and ERK2 mitogen-activated protein kinases 
(MAPKs; FIGURE 6). Activated MAPKs can phosphorylate both cytosolic and 
nuclear substrates and activate transcriptional regulators that control gene 
expression and cell cycle progression. (Repasky GA., 2004) 
 
PI3K consists of a regulatory p85 subunit and a catalytic p110 subunit. Activated Ras 
binds directly to the p110 subunit of PI3K and translocates it to the plasma 
membrane, mediating its binding to receptor tyrosine kinases (RTK) and activation. 
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Activated PI3K converts phosphatidylinositol-4,5-bisphosphate (PIP2) by 
phosphorylation to the phosphatidylinositol-3,4,5-triphosphate (PIP3), which recruits 
a subset of signalling proteins including downstream kinases such as 3-
phosphoinositide-dependent protein kinase 1 (PDK1) and AKT, to the plasma 
membrane, where they are activated. These proteins then affect diverse cellular 
events controlling gene expression, cell metabolism, actin polymerization and cell 
survival. For example, Akt kinase phoshorylates several pro-apoptotic proteins, 
thereby inactivate them leading to survival and increased proliferation in many cell 
types. (Cantley LC., 2002) 
 
Somatic mutations of the three Ras genes causing amino acid changes clustered at 
positions 12, 13 and 61 fail to be stimulated by GAPs and become constitutively 
active in a GTP-bound conformation. These activating mutations in the Ras genes are 
common in cancer and have been found in 30% of all human tumours.  Additionally, 
Ras activation can be enhanced apart from mutations upon increased coupling to 
membrane receptors such as receptor tyrosine kinases, which are also overexpressed 
in most cancer cells. (Campbell PM., 2004) Oncogenic Kras expression promotes lung, 
pancreatic and haematological malignancies (Karnaub AE., 2008) and H-ras 
transformed cells form rapidly growing tumors and give rise to metastasis with an 
autocrine TGF signalling (Oft M., 1996). Aberrant activation of Ras proteins cause 
increased expression of ECM proteases that lead to degradation of the basement 
membrane as well. (Campbell PM., 2004) Thus, together with above mentioned roles 
of Ras effector molecules, Ras activation is an important mediator of tumor cell 
proliferation, transformation, invasion and metastasis. 
 
 
 
 
1.4.1 Dissection of Ras effector pathways in the context of tumorigenesis 
 
The role of a particular effector pathway of activated Ras in mediating invasive and 
proliferative capability of tumors has been searched for intensively. Dissection of Ras 
downstream signalling was determined by using both effector specific low molecular 
weight inhibitors and effector specific mutations in the core Ras effector domain 
resulting inefficient binding of Ras to different effectors. (Campbell PM.,2004) 
(FIGURE 7) 
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FIGURE 7 | Experimental approaches to study Ras effector function.  
                      (Campbell PM., 2004) 
 
 
It has been found, that all effector mutants of activated H-ras were able to induce 
tumorigenesis in NIH3T3 cells, without respect to the specific pathway activated. 
However, only Raf/MAPK activated Ras-transformed cells could cause metastasis. 
(Webb CP., 1998). Additionally, oncogenic Ras transformed but still fully polarized 
EpH4 mammary epithelial cells require a hyperactive Raf/MAPK pathway for EMT 
in vitro and metastasis in vivo, whereas a hyperactive PI3K pathway alone was not 
sufficient to establish metastasis. In contrast, elevated PI3K, but not MAPK signalling 
in EpH4 cells causes cell hyperproliferation in vitro and rapid tumor growth in vivo, 
suggesting that MAPK mediated EMT/metastasis and PI3K induced high 
proliferation ability do not depend on the activation of each other. (Oft M., 1998; 
Janda E.,2002) 
 
 
 
1.4.2 Cooperation of Ras with TGF  
 
Since TGF signalling is required to drive metastasis in vivo (Oft M., 1998) and 
oncogenic Ras signalling is known to protect cells from TGF induced apoptosis after 
cell cycle arrest. (Oft M., 1996); it is suggested, that in diverse tumor cell types, 
oncogenic Ras cooperates with TGF to induce EMT and metastasis. Moreover, upon 
TGF exposure, oncogenic H-Ras transformed cells form spindle shaped structures 
with an invasive behaviour, maintain EMT and show autocrine TGF signalling. 
(Janda E., 2002) In summary, TGF needs a hyperactive Raf/MAPK pathway to 
stimulate EMT and metastasis. On the other hand activation of PI3K signalling is 
essential for the protection from TGF induced growth inhibition. (Janda E., 2002). 
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1.5 EpH4 derived cell systems   
 
EpH4 cells are spontaneously immortalised, well-polarized and non-tumorigenic 
mammary epithelial cells. TGF induces apoptosis in these cells. In contrast, EpH4 
cells overexpressing oncogenic Ha-ras (RasV12) (EpRAS cells) are tumorigenic and 
undergo EMT upon TGF stimulation in vitro and in vivo, forming fibroblastoid cells 
expressing mesenchymal markers at the expense of epithelial marker proteins. (Oft 
M., 1996). V12 Ras mutants generated by single amino acid substitutions in the 
effector loop of the Ras protein have been introduced in EpH4 cells. These oncogenic 
Ras mutants are not able to activate all effector pathways of Ras. They specifically 
signal either along the MAPK pathway, RasV12-S35 (EpS35), or the PI3K pathway, 
C40-V12–Ras (EpC40). Upon TGFinduction in vitro, EpRAS as well as EpS35 cells 
form spindle-shaped cells expressing vimentin and no E-cadherin and maintain EMT 
via activated MAPK pathway as expected. In contrast, TGF-treated EpC40 cells 
show a migratory fibroblastoid phenotype and redistribution but not loss of plasma-
membrane E-cadherin plus no upregulation of mesenchymal markes such as 
vimentin. This phenotypic change of EpC40 cells upon TGF induction is referred to 
as ‚scattering’. EpC40 cells, that can only hyperactivate PI3K pathway, are incapable 
to drive EMT by TGF signalling, due to the lack of an activated ERK/MAPK 
pathway. However, PI3K pathway stimulates hyperproliferation by protecting cells 
from TGF induced apoptosis; thus EpRAS and EpC40 cells grow in vitro rapidly, 
whereas EpS35 cells, which fail to signal through PI3K pathway, show slower 
proliferation rates compared to EpRAS and EpC40 cells by TGF.  (FIGURE 8) 
 
In vitro characterization of these cells correlates with the in vivo characterization of 
their ex-tumors, as well. EpRAS and EpS35 tumors are cytokeratin\vimentin positive 
and E-cadherin negativ, form fibroblastoid-like cells in culture; while EpC40 ex-
tumors show expression of E-cadherin without vimentin staining and retain 
epitheloid phenotype in culture. Further, the in vivo metastatic capability of these 
cells correlates with in vitro EMT capability induced by TGFβ. Histological analyses 
of lungs of mice injected with EpRAS or EpS35 cells indicate multiple metastases in 
both cases, whereas EpC40 injected lungs remain free of metastases. (Janda E., 2002)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 24 
1.6 EMT specific gene profiling  
 
EpH4-derived cell lines overexpressing different oncogenes in cooperation with 
external signals like TGF show diverse epithelial plasticity changes in culture and 
metastatic ability in vivo. An expression profiling study has been performed on 
different cell pairs before and after TGF induced EMT, including EpRAS, EpC40 
and EpS35 cells, to identify specific genes regulated exclusively during scattering, 
EMT or metastasis. (Jechlinger M., 2003) 
 
The characterization and identification of signalling pathways in tumorigenesis has 
been performed by using mRNA expression profiling so far. However, total mRNA 
levels only partly reflect the protein levels because of post-transcriptional/trans-
lational regulation. To overcome this limited correlation of transcript and protein 
levels, polysome-bound mRNA instead of total mRNA has been profiled in arrays 
yielding isolation of both translationally and transcriptionally controlled genes. 
(Mikulits W., 2002)  
 
Applying this method to high density arrays, genes have been identified, which are 
translationally up- or downregulated specifically during cell polarity, invasiveness, 
EMT and metastasis. The candidate genes were selected due to changes in polysome 
bound mRNA expression versus free mRNA expression in cell pairs undergoing 
EMT, but not in those pairs undergoing other or no epithelial plasticity changes . As 
a result, more than 30 genes have been found to be specifically regulated during 
complete EMT and metastasis. (Jechlinger M., 2003) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8 | Different epithelial cell plasticity of EpH4-derived cells 
                       (Jechlinger M., 2003) 
 apical markers, red dots; basolateral markers, green/pink squares;  mesenchymal markers, red fibrils 
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1.7 Tumor stroma 
 
Epithelial cells require stromal influences to control normal development and 
maintain cellular functions and tissue integrity. Stromal cells comprise fibroblasts, 
smooth muscle cells, adipocytes, inflammatory and endothelial cells. During 
carcinogenesis, cancer cells also induce changes in their microenvironment and alter 
the tumor associated stroma. At the same time modified ECM and stroma interact 
with tumor cells and contribute to tumor growth and metastasis. (Liotta LA., 2001; 
Elenbaas and Weinberg, 2001)  
 
This tumor-stroma interaction functions bidirectionally and is dynamic. The 
participation of the tumor microenvironment in tumor progression and invasiveness 
is supported by fibroblast like cells, immune cells, ECM and angiogenic factors. As a 
consequence, all carcinomas become complex mixtures reflecting not only their own 
genomes, but also of the surrounding environment. Indeed, in many of the common 
carcinomas (like breast, colon, and pancreas) the majority of tumor mass, in some 
cases over 90%, is made up by the stroma. (Elenbaas and Weinberg, 2001)  
The cross-talk between tumor and host involves heterotypic cell signalling and 
secreted molecules such as growth factors, cytokines, chemokines, matrix degrading 
enzymes, proteases and ECM proteins that provide cell motility. In turn, these 
molecules stimulate angiogenesis and inflammation; activate and modify 
surrounding tissues and cells such as fibroblasts, alter ECM, generating additional 
secretion of growth factors and proteases. (Olivier De Wever and Marc Mareel, 2003; 
Mueller and Fusenig, 2004) 
 
Growth factors play an essential role in carcinomas; TGF induces metastasis and 
elevates platelet-derived growth factor receptor (PDGFR) signalling, which also 
enhances invasiveness of carcinomas (Jechlinger M., 2006). Angiogenic growth factors 
such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) 
drive endothelial cell proliferation and motility, thereby supporting tumor 
progression and metastasis. (Carmeliet P., 2000) Overproduced cytokines recruit 
innate immune cells, such as lymphocytes, macrophages and neutrophils to the 
tumor. Infiltrating immune cells promote tumor growth and invasion by 
contributing to angiogenesis and ECM remodelling through expression of a range of 
proteases, chemokines and pro-angiogenic factors like VEGF, TGFβ or PDGF. (Pollard 
JW., 2004; Fusenig and Mueller, 2004) 
 
An important modification of tumor stroma is the differentiation of fibroblasts into 
myofibroblasts via cancer cell derived cytokines like TGF, or PDGF, which 
stimulates their further proliferation. Myofibroblasts are also called carcinoma 
associated fibroblasts (CAFs). They have features intermediate between smooth 
muscle cells and fibroblasts. They are spindle shaped mesenchymal cells and are 
involved in tumor progression and metastasis by secreting pro-migratory ECM 
components, growth factors, cytokines and overexpressing serine proteases, matrix 
metalloproteinases (MMPs) that degrade and remodel the ECM. (Olivier De Wever 
and Marc Mareel, 2003; Fusenig and Mueller, 2004) 
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In many human carcinomas such as lung, breast, liver and colon, the presence of 
myofibroblasts correlate directly with the invasive and metastatic state of tumors. 
(Olivier De Wever and Marc Mareel, 2003) 
 
Increased expression of serine- and cysteine proteases as well as  MMPs secreted by 
inflammatory cells and CAFs lead to ECM remodelling, which is also required for 
angiogenesis and invasion of tumor cells. (Elenbaas and Weinberg, 2001) Hence, the 
tumorigenic and metastatic capacity of epithelial cell drived tumors depends 
strongly on the reactive stroma (FIGURE 9).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 9 | Heterotypic signalling between tumour cells and activated stroma  
                       Mueller and Fusenig, 2004 
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1.8 The effects of proteases on tumor cells and stroma 
 
Proteases are highly abundant in the extracellular milieu of tumors. They include 
serine-, cystein-, aspartic acid- and metalloproteinases and are upregulated in 
different tumours. Beside tumor cells, diverse cell types in the tumor 
microenvironment such as myofibroblasts, inflammatory and blood vessel cells 
produce certain proteases as well. Proteases are able to modify tumor stroma and 
remodel ECM. Concerning their paracrine effects on carcinoma cells they cleave and 
activate a plethora of factors and ECM components, thereby generating reactive 
cleavage products and releasing many tumor promoting factors. Proteases are also 
involved in metastasis, due to their ability to break down ECM and basement 
membranes and thus allowing cells to invade surrounding tissues and enter the 
bloodstream. As mentioned, apart from ECM degradation, proteases have an 
important role in liberation and activation of growth factors and cytokines that are 
sequestered within the ECM scaffold. (Fusenig and Mueller, 2004; Elenbaas and 
Weinberg, 2001) 
 
Another important target of proteases is the family of Protease activated receptors 
(PARs). PARs are involved in tumor growth, invasion and angiogenesis through 
activation of downstream signalling cascades in response to various proteases. PARs 
are overexpressed in several cancer types. High expression levels of PAR1 were 
found in highly metastatic breast carcinoma cell lines indicating a correlation with 
the invasive features of a tumor. (Arora P, 2007; Yin yong-Jun, 2003)  
 
 
1.8.1 Proteases that are involved in tumor – stroma communication 
 
Serine proteases: Most prominent members of the serine type protease family with 
known important function in tumor progression are those of the plasminogen system 
(PA-Plg system) - including Plasmin, uPA, tPA -, Kallikrein and Thrombin. They are 
described as enzymes cleaving and activating diverse latent growth factors. For 
instance, plasmin activates TGF, hepatocyte growth factor (HGF) and FGF, thereby 
stimulating tumor growth and invasiveness. (Rakic JM., 2003) Kallikrein shows also 
aberrant expression and dysregulated proteolytic activity in adenocarcinomas. 
(Borgoño and Diamandis, 2004)  Kallikreins interact with PARs and determine tumor 
cell fate. Moreover, uPA, tPA and Kallikreins activate receptor-bound urokinase 
plasminogen activator, which activates latent growth factors. (Borgoño and Diamandis, 
2004; PA-Plg system will be discussed in the next chapter in more detail.) Thrombin 
mediates cell migration and induces invasion and angiogenesis. MMP-1 and 
thrombin can cleave PAR1 and activate its downstream signalling pathways. (Elzer 
KL., 2010) In addition, the PA-Plg system induces tumor progression by activating 
MMPs. (Stetler-Stevenson G.W., 2001) 
 
 
 
 28 
MMPs are a family of >21 extracellular or transmembrane endopeptidases which 
require zinc metal ion for their activity. They are able to cleave highly diverse 
substrates, including ECM components, growth factors and some proteases like 
plasminogen. MMPs have distinct physiological roles in normal cells, such as wound 
healing or tissue remodelling and also in pathological conditions like tumorigenesis. 
(McCawley L.J. and Matrisian L.M., 2001; Egeblad M. 2002)  
 
Many members of the MMP family contribute to tumor progression and invasion, 
while multiple other members have antitumorigenic effects. For instance, MMP-3, 7, 
9 and 12 can process plasminogen in vitro to generate an anti-angiogenic molecule 
“angiostatin”. (McCawley L.J. and Matrisian L.M., 2001) Together with this, MMPs 
have been shown to be implicated in the invasive activity of tumor cells and in 
endothelial cell formation as well. (Mignatti and Rifkin, 1993) Various studies 
involving loss of a single MMP resulted in reduction of tumor development and 
metastasis. For example, in the absence of MMP-9 and -2, tumor growth was 
attenuated and MMP-9 null mice also demonstrated decreased angiogenesis. (Bergers 
G, 2000) Unlike the PA/Plg system, which is activated in all cancer types, specific 
MMPs are selectively overproduced in various kinds and stages of cancer. Since 
there are MMPs with either activatory and inhibitory function on cancer 
development, the unexpected, unsuccessful outcome of clinical trials using MMP 
inhibitors active on several MMPs is understandable. (Coussens L.M., 2002; Egeblad M. 
2002) 
 
Cathepsins belong to the aspartic and cystein type proteases localized in lysosomes, 
however in several human cancers they are secreted facultatively as a consequence of 
lysosomal dysfunction. Indeed altered expression and activity of multiple cystein 
cathepsins like B, L or D have been found in various malignant tumors. (Jedeszko C., 
2004) For example, inhibition of cathepsin L in invasive human melanoma cell line 
prevented tumor growth and reduced metastasis. (Frade R., 2008). Some cathepsins 
were also in the list of EMT-specific genes from the polysome-bound mRNA screen  
(Jechlinger, M, 2003) 
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1.9 The Plasminogen System 
 
Activation of the fibrinolytic cascade and of many other proteolytic processes 
requires conversion of plasminogen to the plasmin. Plasminogen is secreted in 
inactive zymogene form and becomes activated after being cleaved between amino 
acid residues R560-V561 by urokinase or tissue type plasminogen activators (uPA 
and tPA). The active form, Plasmin, consists of two disulfide linked polypeptide 
chains and has a size of about 90kDa. Plasminogen is synthesized mainly in the liver. 
In blood, concentrations of approximately 2µM are measured, while 40% of 
plasminogen are present extravascularly. A wide/diverse range of cell surface 
molecules can serve as plasminogen receptors in eukaryotes. They are responsible for 
localized activation of plasminogen. The most frequent and sufficient criteria for 
plasminogen binding is the presence of surface exposed carboxyl terminal lysines 
(eg. α- enolase, annexin II) or without expression of terminal lysines when integrins 
are synthesized or even exposed at the cell surface (eg. M2 on neutrophils). 
Plasminogen also binds to integrins M2 and 51 in a lysine dependent manner. 
(Castellino and Ploplis, 2005; Andreasen P.A., 2000)  
 
tPA and uPA, which convert plasminogen into plasmin, also belong to the serine 
protease family. Usually, tPA activates plasmin intravascularly for thrombolysis in a 
fibrin dependent manner, whereas uPA acts independently of fibrin, generating 
plasmin for pericellular proteolysis events including ECM degradation. Like 
plasmin, uPA is secreted as an inactive pro-enzyme, which binds to the urokinase 
receptor (uPAR), a cell surface protein tethered by a glycosylphosphatidylinositol 
(GPI) to the cell membrane. Hence, activation of plasminogen occurs at the cell 
surface. As a positive feed-back loop, plasmin catalyzes the cleavage of uPAR bound 
pro-uPA and thus, promotes the activation of receptor bound uPA. Kallikrein, 
Cathepsin B and blood coagulation factor XIIa have also been shown to activate pro-
uPA in vitro. In addition to plasminogen, uPA can convert latent hepatocyte growth 
factor/scatter factor (HGF/SF) and macrophage-stimulating protein into their active 
forms. HGF/SF has been reported to affect cell motility and cellular levels of u-PA 
and u-PAR. (Andreasen P.A., 2000) 
 
Independently of plasmin signalling, uPAR contributes to cell adhesion, proliferation 
and migration through intracellular signalling. Since GPI-anchored uPAR has no 
intracellular domain, it cannot propagate signal transduction alone, but utilises many 
different transmembrane molecules and receptors through protein/protein 
interaction. So far, uPAR has been proposed to interact with ECM protein 
vitronectin, integrins, G-protein coupled receptors and tyrosin kinase receptors like 
EGFR or PDGFR. (Blasi and Carmeliet, 2002; Smith and Marshall, 2010) 
 
There are many physiological inhibitors and regulators of the PA-Plg system which 
ensure a fine tuned and sophisticated regulation of activity. PAI-1 and -2 are the 
inhibitors of plasminogen activator, while 2-antiplasmin (2AP) directly inhibits 
plasmin. They are all members of the serpin superfamily of serine proteases 
inhibitors. (Andreasen P.A., 2000)  
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Binding of plasmin to its receptors via the lysine binding site, results in elevated 
activation of plasminogen and also preservation of the protein from circulating 
2AP, which binds and inactivates only the unbound form of plasmin. As an 
opposite, aprotinin, a serine proteases inhibitor with a broad substrate specify, can 
inactivate both soluble and receptor bound plasmin through the association with its 
active site. (FIGURE 10; Andreasen PA., 1997) 
 
Plasmin primarily has its function in the blood coagulation system, where it 
degrades fibrin-containing thrombi. Beside this, having a broad substrate specifity, it 
is also able to degrade many extracellular matrix proteins such as fibronectin, fibrin, 
laminin and vitronectin. Through this, plasmin intensively contributes to the 
degradation of cell-cell and cell-ECM barriers and thus facilitates cell migration. As a 
consequence, plasmin participates in important processes of tissue remodelling, e.g. 
during embryogenesis, angiogenesis, wound healing and pathological events like 
cancer dissemination. (Castellino and Ploplis, 2005). Plasmin can cleave and activate 
several metalloproteinases, cytokines and growth factors stored in the ECM such as 
TGF, VEGF, FGF, which all have a role in tumor growth, invasion and metastasis. 
(Mignatti and Rifkin, 1993; Rakic JM., 2003; Andreasen PA., 1997) Another potential 
mechanism how plasmin affects cellular processes and its downstream effector 
molecules may involve PAR1 activation and MAPK dependent signalling pathways. 
(Pendurthi UR., 2002) 
 
Expression of uPA, plasminogen, uPAR and PAI-1 is enhanced during cell migration. 
Moreover, plasmin activity induces cell migration, and 2AP and other plasmin 
inhibitors, e.g. urinary- and bovine pancreas trypsin inhibitors prevent invasion. 
Besides, plasminogen activation needs uPAR bound uPA, to induce ECM 
degradation in vitro, indicating that cells require uPA catalyzed plasmin activity for 
a maximum invasion capability through the ECM. Thus, plasmin generation by uPA 
may be the rate-limiting factor for tumor invasion and metastasis formation. 
(Andreasen PA., 2000, Rakic JM., 2003) 
 
In breast cancer, high expression levels of uPA, uPAR and PAI-1 in cancer cells and 
more strongly in fibroblasts correlate with malignancy, invasiveness and tumour 
size. (Dublin E., 2000). PAI-1, although preventing dissemination of cells at high 
levels, may be required for a controlled proteolytic activity of plasmin, whereas PAI-
2 regularly inhibits invasion in vitro. (Andreasen PA., 2000, Rakic JM., 2003) 
 
The essential role of plasminogen for tumor growth and metastasis has been shown 
in studies of Plg knockout mice. Plg-/- mice expressing Polyoma middle T antigen 
(PyMT) under the breast specific MMTV promoter resulted in decreased lung 
metastasis, while PyMT-driven breast carcinoma formation was not affected. (Bugge 
TH., 1998) In another study, fibrosarcoma cell transplanted Plg-/- and wt mice both 
developed sarcomas, but Plg deficient mice had a significantly reduced tumor 
burden. (Curino A., 2002) Thus, these reports indicate that plasminogen has an 
important role in tumor progression and metastasis.  
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However, the observation that metastasis was impaired but not absent in Plg 
deficient mice suggests that development and dissemination of tumors can be also 
influenced by other proteases that show partially overlapping functions with 
plasmin.  
 
Aprotinin, a non-specific broad serine protease inhibitor, inhibits plasmin, 
plasminogen activator or kallikrein. Since proteases have tumor promoting roles, 
aprotinin is thought to be a good therapeutic tool to prevent tumor development, 
resection and metastasis. Moreover, it is been used to inhibit primary tumor growth 
of various cancer types in animals. However, inhibition of plasmin dependent 
fibrinolytic system increases thrombosis and blood coagulation factors. Many 
metastatic cells are associated with thrombi that actually have been demonstrated to 
enhance the survival of metastatic cells, allowing their retention in the secondary 
organs. Therefore aprotinin failed to be beneficial in metastatic cancer therapy. 
(Turner G.A, 1981) For instance, experimental metastasis assays of B16F10 murine 
melanoma cells showed increased metastases formation in aprotinin treated animals. 
(Kirstein J.M., 2009) 
 
Since this study focuses on the mechanism of ILEI, which has been found to be 
processed by plasmin (see next chapter), data on the Plg/PA system supported our 
experiments and conclusions and were thus highly relevant in our studies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10 |     the plasmin/plasminogen activators system, its function and regulation 
                             (Smith WH. and Marshall CJ, 2010) 
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1.10 ILEI 
 
Interleukin like EMT inducer (ILEI) belongs to a novel cytokine gene family FAM3, 
which was identified by searching for novel four--helix-bundle cytokines in 
genomics databases (Zhu and Xu, 2002). Later structural analyses indicated, however, 
that the -helices in ILEI did not really resemble the four--helix-bundle in typical 
cytokines. Four genes belong to the FAM family, i.e. FAM3A, FAM3B, FAM3C 
(which is ILEI), and FAM3D, each encoding a protein of 224-235 amino acids with a 
hydrophobic signal peptide. Northern blot analysis has indicated that FAM3D is 
expressed in high levels in the placenta, FAM3B in the pancreas, and FAM3A and 
FAM3C in almost all tissues. Additionally, FAM3C has been reported to be expressed 
in the inner ear and suggested a role in its development. (Pilipenko and Reece, 2004) 
  
FAM3C has been identified and referred to as ILEI in a polysome bound expression 
profiling screen for EMT-specific genes. During EMT and metastasis, TGF 
upregulates ILEI exclusively at the translational level. (Jechlinger M., 2003) It is a 
facultatively secreted protein. Exogenous ILEI overexpression in non-tumorigenic 
(EpH4), tumorigenic but non-metastatic (EpC40) and tumorigenic and metastatic 
(EpRAS) mouse mammary epithelial cell lines has resulted in complete EMT, 
elevated tumor growth and metastasis. In EpH4 cells, however, ILEI alone caused a 
reversible EMT and weak metastasis. Full EMT induction by ILEI was dependent on 
oncogenic Ras signaling but independent of TGFβ signaling. It causes accelerated 
tumor growth as a consequence of stimulation of EMT without an effect on cell 
proliferation. Additionally, ILEI expression increases phosho-ERK levels in both 
EpH4 and EpC40 cells, which have only basal ERK/MAPK activation. Furthermore, 
ILEI stimulates upregulation of diverse cytokines, chemokines and growth factors 
and their receptors like PDGFR, which is known to be necessary in tumor 
progression. ILEI-induced EMT and -metastasis could be inhibited or reversed by 
RNAi-mediated knock down of ILEI in EpRAS- or mesenchymal EpRasXT cells 
(EpRas cells after TGF-mediated EMT), the latter failing to maintain EMT and 
regaining an epithelial cell phenotype. In human carcinogenesis, elevated ILEI levels 
and altered localization correlate with survival rates. (Waerner T et al., 2006) 
 
In some epithelial tissues like uterus, prostate or lung, expression of ILEI protein was 
not detectable by immunohistochemistry, but in other secretory epithelia 
(duedonum, pancreas, colon) and in certain tumors, ILEI localization showed dot-
like, suprabasal structures, most likely representing Golgi- or trans-Golgi-network 
(TGN) structures. However, in many metastatic tumors ILEI was found to be 
delocalized as small vesicles throughout the entire cytoplasm of tumor cells, which 
might reflect an enhanced secretion of the protein, which actually correlates with an 
enhanced translation and secretion levels of ILEI during EMT and metastasis. 
(Waerner T et al., 2006). TGF upregulates both intracellular and secreted ILEI levels 
in EpH4 and EpRAS cells, at least partially by increasing the translation of the 
protein, indicating that ILEI acts downstream of TGF during EMT (Waerner T et al., 
2006). 
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A recent report has revealed the mechanism of TGF stimulated ILEI translation. 
TGF mediates phosphorylation and inactivation of hnRNP E1 protein. In its active 
form this protein binds to the 3’ untranslated region of the ILEI transcript and 
represses its translation. TGF activated release of hnRNP E1 from ILEI mRNA 
results in increased translational activation of ILEI. (Chaudhury A., 2010)  
 
 
1.10.1 Biochemical properties of ILEI protein 
 
ILEI is a secreted protein. It consists of 227 amino acids (aa) with a signal peptide at 
its N terminus. (FIGURE 11) Western blot analyses showed that secreted ILEI is 
shorter than its intracellular form. (FIGURE 12 left part) Indeed, mass-spectrometry 
(MS) data confirmed that secreted ILEI lacks 17 amino acids at the N-terminus, which 
contains arginin/serine aminoacids as a potential cleavage site, in addition to the 
signal peptide. Thus, ILEI might be processed after synthesis.  
 
Additionally, serum containing medium is sufficient to generate the short form of 
ILEI, whereas under serum free conditions ILEI is secreted but preferentially retains 
the MW of the full length form, indicating that the protein is processed 
extracellularly. In cell-free assays, serum alone is able to cleave ILEI. (FIGURE 12) 
Presumably, ILEI might be processed by serum proteases. In vitro, Aprotinin, a 
broad spectrum inhibitor of serine type proteases, efficiently inhibits ILEI cleavage 
(FIGURE 13). Finally, the serine type protease, plasmin, has been proven to be 
specifically able to cleave full length ILEI at the arginin/serine position. (FIGURE 14) 
(Agnes Csiszar, unpublished data)  
 
Plasmin is widely overexpressed in tumors, it also has an important role in releasing 
growth factors and cytokines adhered to the ECM. (Detailed information about 
plasmin has been given in previous chapter) It remains to be clarified, whether 
plasmin is the only protease to generate the short form of ILEI, but pilot experiments 
suggest that closely related proteases also cleave ILEI in vitro.  
                       
 
 
              Full length (intracellular) 
 
 
                                       
  
   
 
 
 
FIGURE 11 |    schematic drawing of ILEI structure 
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FIGURE 12 | Serum alone is able to generate the short form of ILEI 
                         C.M.; conditioned medium from respective cells 
 
 
 
 
 
 
FIGURE 13 | Proteases inhibitors with their targets (left) and inhibition of ILEI 
cleavage by aprotinin (right)  
 
 
 
 
 
 
FIGURE 14 | Plasmin is able to cleave ILEI. 
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1. 11  Aim of this study 
 
In the first part of my diploma thesis, I studied the mechanism of proteolytic 
cleavage of ILEI in vitro and the physiological relevance of ILEI cleavage in vivo. We 
questioned whether ILEI-directed tumor growth and metastasis depend on its 
cleavage. Furthermore, we studied potential connections between ILEI processing 
and secretion by addressing the question whether or not cleaved ILEI might 
stimulate its own expression and secretion directly in an autocrine manner via 
binding to putative ILEI receptors.  
 
In the second part, I performed the initial characterisation of a doxycyclin inducible 
ILEI overexpressing transgenic mouse model using ex vivo and in vivo assays. The 
inducibility and tissue pattern of ILEI transgene expression were analysed in various 
organs of mice before and after induction.  
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2. RESULTS 
 
2.1. ILEI CLEAVAGE ASSAYS 
 
2.1.1 Cleavage test of ILEI by serum from Plasminogen knock out mice 
 
To determine, whether plasmin is the only physiological protease responsible for 
ILEI cleavage, we made use in the availability of plasminogen knock out (Plg KO) 
mice. Blood sera were collected from Plg knockout mice and their wild type and 
heterozygous littermates. Purified full length ILEI-flag protein was incubated in 10% 
(v/v) serum for 8 hours at 37°C.  
 
 
 
 
 
FIGURE 15 |   Plg-/- mouse serum able to cleave ILEI 
 
 
ILEI was cleaved in all types of mouse sera, including Plg KO mouse serum which 
cleaved less effectively, indicating that there should be other proteases with the 
ability of ILEI processing.  
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2.1.2 Cleavage test by other serine type proteases 
 
We were wondering which other proteases might be able to process ILEI at the same 
site as plasmin does. As the plasmin type serine proteases thrombin and kallikrein 
have very similar cleavage recognition sites to plasmin, they were tested in in vitro 
cleavage assays. Together with the full length form of ILEI, the secreted protein 
(short form) was also purified and incubated with proteases. This would allow 
identifying only the proteases that process ILEI at its R/S site specifically generating 
a protein in ~19kDa size.    
 
 
 
 
 
FIGURE 16 |   cleavage test of full length and secreted ILEI by other plasmin type  
proteases  SN: supernatant 
 
 
Both, Kallikrein and thrombin were also able to cleave ILEI. However, much higher 
amounts of proteases were required to generate significant amounts of cleaved ILEI. 
In case of kallikrein and thrombin 5 times and 400 times more activity had to be 
added to the reaction, respectively, as compared to plasmin. Thus, in our tests 
plasmin was proven to be the most active protease for ILEI. All these proteases 
processed only full length ILEI, whereas secreted ILEI remained intact, suggesting 
that the cleavage occurs specifically at the propeptide region.  
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2.1.3 Generation of ILEI mutants 
 
To investigate the physiological role of ILEI cleavage, a series of respective ILEI 
mutants were generated. Wild type (wt) and mutant ILEI proteins were C terminally 
fused to a Flag epitope tag to enable detection of the overexpressed protein 
separately from endogenous ILEI. Two different types of ILEI mutants were used for 
further analysis. One group contained ILEI cleavage mutants that had point 
mutations at the cleavage recognition site, where arginin (R) and serine (S) amino 
acids were substituted with the hydrophobic amino acid phenylalanine (F) and acidic 
aspartic acid (D), therefore this mutants are referred to as ILEI-FD or ILEI-DF. These 
mutants should not be substrates for the responsible proteases. The second group 
was the ∆pro-peptide mutants that lacked the ‚pro-peptide’, which has been 
proposed to be cleaved off after secretion of ILEI. The ∆N-RS-ILEI mutant was 
generated starting with RS amino acids, because they might be essential for the 
secretion of protein.  
 
 
 
 
 
 
 FIGURE 17 |   schematic representation of the ILEI protein and its mutant forms used in 
this study 
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These wt and mutant ILEI proteins were overexpressed in EpRAS and EpC40 cell 
lines. First, we analyzed the intracellular and secreted ILEI levels of these cells by 
Western blotting.  
 
 
 
 
FIGURE 18 |   Intracellular and secreted ILEI levels of generated EpC40 cells over- 
                           expressing wt and mutant forms of protein.  
                           C.M.: conditioned medium of cultivated cells.  
 
 
As expected, the secreted form of the cleavage mutants were indeed no more cleaved 
and run prefentially at higher molecular weights, and the intracellular forms of ∆pro-
peptide mutants were already shorter than wild type intracellular ILEI.  
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Secondly, we examined the cleavage of the generated wt and mutant forms of ILEI in 
vitro. For this, the proteins were purified from the overexpressing cells and the same 
cleavage assay was performed using the same proteases as described before for wt 
ILEI. 
 
 
 
 
FIGURE 19 |   Cleavage test of mutant ILEI forms with plasmin, thrombin and kallikrein  
proteases 
 
 
All three proteases, plasmin, thrombin and kallikrein, were again able to cleave wt-
ILEI. In contrast, the ILEI mutants indeed functioned no longer as efficient substrates 
of the proteases, showing that the mutants were generated successfully. However, 
we observed differences in the ratio of cleaved and non-cleaved ILEI compared to the 
previous cleavage assay, although the same amount of proteases were used. 
(compare Figure 16 and 19) Cleavage efficiency of the ILEI protein often depended 
on purification quality or pH of the purified protein. In the two experiments shown, 
separately purified proteins were used, which might be responsible for the slightly 
different results to some extent.  
In these experiments, we also used higher amounts of the protein to overcome the 
loss by unspecific protein degradation, that was most prominent in the plasmin 
assay.  
 
In addition, we observed different secretion levels of the different ILEI forms in the 
overexpressing cells. On the one hand, cells overexpressing the cleavage mutant 
forms secreted less ILEI than those with wild type ILEI. In contrast, cells 
overepressing the ILEI mutants lacking the propeptide (∆pro-peptide mutants), 
which bypass the need of proteolytic processing, secreted ILEI at even higher levels. 
Accordingly, it appeared that ILEI secretion levels might be linked to the cleavage of 
the protein.  
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2.1.4 In vivo tumorigenesis experiment 
 
To analyse the physiological role of ILEI cleavage on tumorigenesis, we injected 
EpC40 cells overexpressing wt and mutant forms of the protein into nude mice. 
Third and fourth mammary gland fat pad of mice were injected with 2x105 of these 
cells. As mentioned before (chapter 1.5 and 1.9.1), in the tumorigenic but non-
metastatic EpC40 cells, overexpression of ILEI caused accelerated tumor growth and 
induced full EMT and metastasis.  
The mice were sacrificed ~40 days after injection and mammary tumors were 
excised. A part of excised tumors were analysed in immunohistochemistry and the 
rest was recultivated for further experiments.  
 
 
 
 
FIGURE 20 |   Tumor growth kinetics of EpC40 mammary tumors overexpressing wt and 
                           mutant forms of ILEI 
                           Error bars show standard error of means (SEM), * marks P<0,05 and ** 
P<0,002 calculated by two tailed student’s t-test. 
 
 
As expected, EpC40 wt-ILEI overexpressing cells showed significantly elevated 
tumor growth rates as compared to the control cells. Cleavage mutant 
overexpressing cells had very low tumor growth capacity, similar to control cells. 
Interestingly, the ∆pro-peptide mutant overexpressing cells showed strongly 
accelerated tumor growth as compared to wt-ILEI overexpressing EpC40 cells.  
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FIGURE 21     Tumor masses of different ILEI forms overexpressed in EpC40 mammary 
tumors Error bars show standard error of the mean (SEM). *: P<0,02, **: 
P<0,007 
 
 
Differences in tumor growth kinetics were also reflected in tumor weight, 
determined after sacrificing the mice and isolating the mammary tumors. Cleavage 
mutants and control cells formed small tumors. Wt-ILEI overexpressing cells formed 
bigger tumors, which were, however, still smaller than the tumors formed by cells 
overexpressing the ∆pro-peptide mutants.  
 
As a consequence of these results, we postulated that ILEI cleavage might play an 
important role for its function and the generation of the short form could be required 
for accelerated tumor growth and tumor burden. However, we could not exclude, 
that different tumor formation ability of these cells might have different reasons, 
such as different secretion levels of ILEI, which might be responsible for the different 
tumor growth rates observed. Therefore, we tested by inhibiting ILEI processing in 
vivo,  whether the cleavage of the protein would be the main process required to 
stimulate tumor growth  
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2.1.5 In vitro aprotinin pilot experiment 
 
Earlier in vitro cell free assays showed that the broad spectrum serin protease 
inhibitor aprotinin was able to prevent ILEI cleavage caused by fetal calf serum. 
(Chapter 1.9.2) Here, we first checked if aprotinin would be similarly efficient on 
mouse serum-induced ILEI cleavage.  For this, purified wt and mutant ILEI proteins 
were incubated with mouse serum in the presence or absence of aprotinin.  
 
 
 
 
FIGURE 22 |    Cleavage of ILEI by mouse serum (red arrow) and its inhibition via 
aprotinin  
 
 
Wt ILEI was cleaved by mouse serum, whereas the mutants were not. Importantly, 
aprotinin could inhibit the cleavage of wt-ILEI by mouse serum (FIGURE 22). Thus, 
aprotinin appeared as a reasonable tool to inhibit ILEI cleavage in vivo . Since 
aprotinin has been used in mouse experiments and has already been used in clinical 
trials, a large body of information was available concerning  dosage calculation and 
pharmacokinetics of this inhibitor.  
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2.1.6 In vivo tumorigenesis experiment with aprotinin treatment  
 
An in vivo tumorigenesis experiment was performed as described above, except that 
in this experiment a subset of mice were treated with 4000 KIU of aprotinin by i. p. 
injection every day over the whole period of the experiment. This was necessary, 
since aprotinin fails to maintain its in vivo activity after 24 hours. Again, ~40 days 
after injection mice were sacrificed, mammary tumors were excised, weighed and 
fixed for immunohistochemical analysis (2.1.7) 
 
Aprotinin treated mice injected with wt-ILEI overexpressing EpC40 tumor cells 
showed significantly decreased tumor growth rate (FIGURE 23 top) and tumor size, 
(FIGURE 23 bottom) as compared to control mice receiving the same cell injections, 
but no aprotinin treatment. Injection of all the other cell types caused tumors with 
similar, maybe even slightly increased growth rates and tumor sizes in aprotinin-
treated mice as compared to non-treated animals. Thus, ILEI-induced increased 
tumor growth was repressed in case of wt-ILEI, but not in case of the delta pro-
peptide ILEI mutants, indicating that an aprotinin-sensitive protease activity was 
important to generate the processed form of ILEI in vivo, which apparently is 
required for rapid tumor formation.   
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FIGURE 23  Tumor growth rates (upper panel) and tumor weights (lower panel) of  
                      EpC40 mammary tumors overexpressing different forms of ILEI with or  
         without aprotinin treatment. Error bars show standard error of the mean (SEM).  
2.1.7 In vivo characterization of  excised mammary tumors by immunohisto- 
chemistry (IHC)  
 
 
 
Mammary tumors from aprotinin-treated and non treated animals were immunostai-
ned for proliferation and apoptosis markers, E-cadherin /vimentin  EMT marker pro-
teins and ILEI/FLAG proteins. The stained sections were analysed for changes gene-
rated by the inhibitor treatment and for differences between the different cell lines  
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2.1.7.1 Ki67 (proliferation marker) and activated Caspase3 (apoptosis marker) 
stainings 
 
 
 
FIGURE 24 |   Ki67 and actCaspase3 IHC of EpC40 tumors    
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FIGURE 25 |   Quantification of  Ki67 and actCaspase3 positive cells 
                           Error bars show standard error of the mean (SEM). 
 
 
 
No significant changes in proliferation- and apoptotic marker expression of EpC40 
tumors overexpressing wt and mutants of ILEI with/out aprotinin could be detected. 
Aprotinin might slightly decrease the apoptotic activity in all cells, except in wt-ILEI 
overexpressing EpC40 cells. However, enhanced apoptosis in some parts of this 
tumor was not significant. We concluded that apoptotic alterations and proliferation 
capacity were not involved in reduced tumor size of wt-ILEI tumors caused by 
aprotinin. 
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2.1.7.2 Immunostainings for E-cadherin and vimentin  
 
 
 
FIGURE 26   IHC staining for E-cadherin and vimentin in ILEI overexpressing 
                         EpC40mammary tumors 
 
 
Although the staining intensity in all sections was very low, we observed loss of E-
cadherin and upregulation of vimentin in these tumors. Only the control and wt-ILEI 
cells expressed some E-cadherin, but in case of wt-ILEI also vimentin. Cleavage- and 
∆pro-peptide mutant overexpressing EpC40 tumors showed the highest levels of 
vimentin without residual E-cadherin expression. 
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2.1.7.3 ILEI/FLAG stainings 
 
 
 
 
FIGURE 27 |   ILEI and Flag IHC of EpC40 mammary tumors          
 
 
EpC40 control cells expressed very low levels of endogenous ILEI and were negative 
for FLAG, as expected.  
We have observed high levels of ILEI expression in all cells overexpressing the FLAG 
epitope tagged version of wt and mutant forms of the protein and could detect ILEI 
by both ILEI and FLAG antibodies.  
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In the absence of aprotinin treatment, localization of the ILEI protein in EpC40 and 
cleavage mutant-overexpressing tumors showed vesicular dot-like structures, while 
wt- and ∆N-RS ILEI tumors showed ILEI to be more delocalized to the cytoplasm of 
tumor cells.  
In vitro characterization of these cells showed, that ∆pro-peptide ILEI mutant 
overexpressing cells secrete the highest and cleavage mutant ILEI overexpressing 
cells the lowest levels of ILEI. The differences in secretion levels seem to correlate 
with the subcellular localization of ILEI in tumors formed by these cells. Increased 
secretion correlates with higher levels of diffuse cytoplasmic and lower levels of dot-
like granular appearance of the protein. In addition, we observed a shift of 
cytoplasmic ILEI into dot-like granular structures upon aprotinin treatment, which is 
also in correlation with our in vitro findings, that ILEI secretion required higher 
extracellular plasmin levels. Lack of plasmin by using serum free medium resulted in 
lower secretion levels of ILEI, while addition of exogenous plasmin enhanced 
secretion; for details see Chapter 2.2). These results led us to hypothesize that ILEI 
delocalization to the cytoplasm might be due to enhanced secretion of the ILEI 
protein (Chapter 1.9.1). 
 
 
 
2.1.8 In vitro characterization of ex-tumor cells 
 
We were interested to elucidate the molecular mechanisms responsible for the 
observed differences in tumor growth caused by the different ILEI mutants. For this, 
cells of the above described mammary tumors were recultivated and analysed for 
their proliferation rate, morphology and for several cellular markers and activity of 
different signaling proteins, in comparison with the respective cells before injection 
into mice.  
 
 
2.1.8.1 ³H-incorporation in vitro proliferation test 
 
We were wondering, whether differences on tumor formation would derive from 
differences in the proliferation capacity of these cells. We therefore compared the 
proliferation rates of the generated ILEI/ILEI-mutant-overexpressing EpC40 cells 
before injection and of recultivated cells from the respective tumors.  
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FIGURE 28 |   Proliferation rates of EpC40 cells harboring different ILEI forms before and 
after tumor formation in mice 
 Error bars show standard error of the mean (SEM)., cells numbers were normalized to the 
EpC40 control cells (set to 1) 
 
 
Proliferation rates of cells overexpressing wt and mutant forms of ILEI correlated 
neither before injection nor after re-cultivation with the differences in tumor growth 
and size that we observed. For instance, ∆pro-peptide mutants were the ones that 
generated bigger tumors compared to the wt cells. Except that ex-tumor cells 
expressing this mutant proliferated somewhat faster than the other cells (FIGURE 28, 
bottom panel, not significant), there were no significant differences in the prolifera-
tion capacity of any of these cells, similar to what we observed by in vivo IHC 
characterization of these tumors. We concluded that alterations in proliferation 
capacity might not be involved in ILEI induced elevated tumor growth.  
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2.1.8.2 Morphology of recultivated tumor cells  
 
Light-microscopic phase micrographs of the above ex-tumor cells in culture dishes 
were taken and are depicted in FIGURE 29.  
 
 
 
FIGURE 29 |   Morphology of re-cultivated tumor cells in culture dishes 
 
 
As mentioned before (chapter 1.5), EpC40 cells fail to induce EMT in vitro and form 
no metastases in vivo. Additionally, EpC40 ex-tumor cells after recultivation form 
epithelial cell like structures in culture.  
Injected EpC40 control cells and wt-ILEI and ∆pro-peptide mutant overexpressing 
cells have still partially kept their epitheloid phenotype even after they passed 
through a tumor stage. However, cleavage mutant ILEI overexpressing cells looked 
somewhat mesenchymal after recultivation from primary tumors, although this 
mutant had a similarly low tumor growth capacity as EpC40 control cells and formed 
the smallest tumors. However, the fast growing EpC40∆N-RS cells also showed 
regions of mesenchymal looking cells.  
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2.1.8.3 Analysis of cellular markers and signalling proteins of recultivated cells 
 
Recultivated mammary tumor cells were analysed for epithelial and mesenchymal 
marker proteins and for the activation status of some signaling molecules by Western 
blotting.  EpH4 cells, from which EpC40 and EpRAS cells were generated, served as 
epithelial controls. Through this, we could distinguish the changes in markers and 
signaling caused by RasV12C40 oncogenic transformation from those generated by 
the overexpression of different types of ILEI. By testing the cell series before injection 
into mice and after recultivation from tumors, we could also examine the changes 
that occurred in vivo during tumorigenesis probably via the interactions of injected 
cells with their environment.  
    
 
FIGURE 30 |   The regulation of some epithelial/mesenchymal marker and signalling    
proteins in EpC40 tumor cells overexpressing different ILEI forms   
                             pERK: phosphorylated ERK and pAKT: phosphorylated AKT            
* marks whole cell lysate of cell lines before injection, the two following lanes are samples of 
recultivated cells from two independent tumors 
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As expected, intracellular ILEI levels of cells remained similar before and after 
injection. All injected and recultivated cells downregulated E-cadherin and ZO-1, 
most prominently in case of the cleavage and the ∆pro-peptide mutant cells, while 
fibronectin was upregulated in these cell lines after tumor formation. These markers 
correlated positively with the morphology of recultivated cells and with the results 
of immunohistological characterization of the tumors, but do less well correlate with 
the differences in tumor growth rates and tumor weight. Indeed, wt-ILEI 
overexpressing cells were somewhat more epithelial than the others and here they 
still had relative high E-cadherin levels compared to the other cell lines. In contrast to 
this, they formed bigger tumors than control and cleavage mutant cells, which were 
more fibroblastoid-like cells in culture and had much lower tumor growth capacity.   
 
pAKT, pERK and twist levels did not show any significant changes before and after 
injection or between the different cell types with the exception of ∆pro-peptide 
mutant ex-tumor cells, which had elevated levels of pAKT and pERK signalling 
proteins. In fact, EpC40 cells have a mutated active Ras oncogene and are not able to 
signal through ERK/MAPK pathway and have only basal ERK levels. Thus, 
increased pERK signalling should be derived from elevated endogenous Ras 
signalling. Since enhanced pERK levels in ∆pro-peptide mutant cells correlate with 
the elevated tumor growth of these cells, increased ERK signalling in these cells 
might be important and contribute to increased tumor growth rate.  
 
On the other hand, the loss of epithelial markers like E-cadherin in EpC40 ex-tumor 
cells and the same pAKT levels of these cells as EpH4 cells were not in accordance 
with earlier published data on cultivated cells, that had not undergone a tumor 
passage. (Chapter 1.5) 
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2.1.9 In vivo lung colonization assay 
 
So far, we studied the physiological role of ILEI cleavage only in primary tumor 
formation. EpC40 cells are incapable to enter the bloodstream from primary 
mammary tumors and also if these cells are injected directly into the circulation, they 
fail to extravasate and colonise to the lung. However, ILEI overexpression is 
sufficient to make these cells metastatic (Waerner T et al., 2006). To test to what extent 
the different mutant forms of ILEI maintain this function of the protein, we injected 
2x105 of recultivated ex-tumor cells (mature cells) into the tail vein of nude mice to 
assay the metastasis formation capability of these cells. This experiment allows to 
analyse late steps of metastasis: survival in blood, capability of extravasation and 
homing and proliferation ability in the lung, from where tumor cells do not originate. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 31 |   Lung colonization capability of EpC40 cells overexpressing different  
mutant ILEI forms 
Percentage of lung metastatic area driven by EpC40 ex-tumor cells overexpressing 
different ILEI (left), Representative images of H&E stained lungs (right)  
Error bars show standard error of the mean (SEM); for calculation of lung metatstatic area, 
see chapter 5.7.2 
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As published earlier, EpC40 control cells fail to promote large metastases. We 
observed very small micro metastases (~1% of whole lung). wt- and ∆N-ILEI 
overexpressing tumor cells could form metastasis, as expected. Interestingly, by 
measuring total metastatic areas, the difference in the metastatic capacity between 
these cells was not significant, in contrast to primary tumor formation ability of these 
cells, where ∆pro-peptide mutant cells caused much higher tumor growth rates and 
larger tumor sizes (FIGURE 31). From histological analysis of the lungs, it appeared, 
however, that the ∆N-ILEI  mutant cells caused much larger metastases (FIGURE 31, 
right panels) Furthermore, cleavage mutant overexpressing tumor cells were also 
capable to induce some small metastases, but much less than wt cells (10% of whole 
lung), indicating that non-processed ILEI is also able to somewhat promote 
metastasis. It is obvious, however, that cells expressing the constitutively cleaved 
form ∆N-ILEI have strongly enhanced metastatic capacity.  
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2.2 ILEI secretion assays 
 
Since constitutively cleaved, mature ILEI (∆N-ILEI ) shows strongly enhanced 
secretion, there could be a positive feedback loop of mature ILEI stimulating its own 
secretion. We therefore addressed, whether or not the proteases that are responsible 
for its processing might have effects on its secretion as well.  
 
The published data showed that TGF upregulated ILEI translation and secretion. 
(Chapter 1.9.1) After we confirmed that plasmin cleaves ILEI, we wanted to test the 
action of plasmin on the secretion of the protein. We did secretion assays in cell 
culture with and without serum containing medium. 
 
 
FIGURE 32  Stimulation of ILEI secretion by TGF & plasmin in EpRAS and NIH3T3 
                      cells  CM: conditioned medium from cells incubated with medium for 24 hours 
 
 
Cells incubated with serum containing medium showed somewhat higher basal 
secretion levels of ILEI, this, however, did not influence the much higher stimulation 
of secretion obtained after factor/protease treatment (FIGURE 32). 
TGF, indeed, increased both intracellular and secreted ILEI levels within 24 hours. 
Plasmin upregulated secretion levels of ILEI much stronger than TGF. Additionally, 
we observed a slight decrease in the intracellular levels of the ILEI protein after 
plasmin exposure, an effect observed also upon strong stimulation of secretion of 
other proteins.  
The induction of secretion by plasmin was not specific for epithelial cells, since 
plasmin treatment of fibroblasts also enhanced ILEI secretion. 
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2.2.1 Stimulation of ILEI secretion: time course analysis 
 
For the comparison of TGF and plasmin driven induction of ILEI secretion in more 
detail, we performed a time course analysis of ILEI secretion over 24 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 33   Time course of Intracellular  and secreted ILEI levels in EpRAS cells 
                        treated with TGF/Plasmin over 24 hours  
                        C.M. starv.: conditioned medium without serum (starvation medium) 
 
 
 
TGF significantly upregulated intracellular ILEI only after ~8 hours, perhaps as a 
consequence of elevated secretion of the protein. 
In constrast, plasmin induced ILEI secretion very rapidly, at the first time point taken 
(two hours) secretion was already almost maximal. At the same time, a strong, 
almost complete downregulation of the intracellular ILEI protein pool was evident 
after 4 hours. Repeating the time course analysis during the first two hours, ILEI 
secretion was completely turned on after 30 minutes, while nothing happened within 
15 minutes (FIGURE 34)  
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FIGURE 34 |   Induction of ILEI secretion via plasmin occurs within 1 hour. 
 
 
Thus, plasmin enhanced ILEI secretion within less than one hour and it was already 
combined with a decrease of intracellular protein, indicating that plasmin stimulates 
ILEI secretion at the expense of the intracellular ILEI pool. Most likely, therefore, 
plasmin-stimulated secretion occurred via a completely different regulatory 
mechanism as seen with TGF, where TGF primarily acts via upregulating ILEI 
translation, then leading to elevated secretion of the intracellular accumulating 
protein. (FIGURE 33-34) 
 
 
2.2.2 Plasmin dependent ILEI secretion in human cell lines 
 
Above, we showed that Plasmin drives the elevated secretion of ILEI in EpRAS and 
mouse fibroblast cells. This raised the question, if this mechanism might be also 
relevant in the human system and therefore tested several human tumor cell lines.  
 
FIGURE 35   Effects of plasmin on ILEI secretion in different human cell lines 
                       MCF7 and SKBR3 are human breast cancer cell lines and Hela is a human 
                       cervical cancer cell line.  
10mU 
 61 
In Hela and SKBR3 cell lines, plasmin had similar effects on ILEI secretion as in 
EpRAS cells, however increased secretion of the protein was not always tightly 
combined with reduced intracellular levels. No effect of plasmin was seen in MCF7 
cells, which probably differ in the way they trigger ILEI signalling and enhance its 
secretion. In summary we could conclude that plasmin-induced upregulation of ILEI 
secretion occurs also in human cell lines, although to a different extent in the 
different cell lines.  
 
 
2.2.3 Dose dependence of plasmin for elevated ILEI secretion 
 
We determined the minimal concentration of plasmin required to stimulate ILEI 
secretion. All secretion experiments before were done with 10mU plasmin. For this, 
we treated cells with plasmin levels from 0,625mU to 10mU.  
 
 
 
 
FIGURE 36    Less than 1 mU of plasmin is sufficient to stimulate secretion of ILEI 
 
 
 
The lowest amount of plasmin added to the cells was aleady able to fully stimulate 
secretion of the ILEI protein, almost to the same extent as higher amounts, indicating 
that this amount of plasmin already saturates the ILEI secretory system. 
Interestingly, however, we detected uncleaved, full length ILEI in the conditioned 
medium (higher band on Western blot) of plasmin treated cells. The amount of 
uncleaved ILEI decreased stepwisely with the increasing amount of plasmin added 
to the cells. These results suggest that more plasmin might be required, to cleave 
secreted ILEI, than to trigger secretion of the protein. For the exact determination of 
the minimal plasmin amount needed to enhance secretion, one should repeat this 
experiment with much lower doses of the enzyme.  
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2.2.4 Protease-dependent ILEI secretion 
 
There are several potential mechanisms how plasmin could lead to elevated ILEI 
secretion. One hypothesis is that elevated secretion of ILEI is a consequence of an 
autocrine positive feedback loop and plasmin is needed only to generate the cleaved, 
active form of ILEI to induce ILEI signaling. Alternatively, plasmin could play a 
specific role in ILEI secretion that is independent of ILEI cleavage and would act 
through plasmin signaling. To distinguish these two possibilities, we tested other 
enzymes that were able to generate the short form of ILEI, whether they would be 
able to enhance secretion of the protein in EpRas cells as well.  
 
 
 
 
FIGURE 37 |   Intracellular and secreted ILEI levels in EpRAS cells subjected to 
                           Plasmin and other ILEI processing proteases for 24 hours  
 
 
Plasmin induced again ILEI secretion in both serum free and 4% serum containing 
medium in EpRas cells. In contrast, thrombin did not influence secreted and 
intracellular ILEI protein levels. Kallikrein was able to stimulate protein secretion, 
but only in serum containing medium, and to a clearly less extent than plasmin. 
Intracellular levels of the protein decreased upon enhanced secretion, clearly after 
plasmin and also slightly after kallikrein treatment.  
This experiment showed that, cleaved ILEI is unlikely to trigger its own secretion 
directly, rather, Plasmin might induce secretion independently of ILEI cleavage. The 
fact that kallikrein became a potent inducer of secretion in the presence of serum is 
most probably due to its function as an activator of urokinase plasminogen activator 
(uPA) and plasminogen, since serum contains all the components of the plasminogen 
system. This would be in line with the assumption, that only plasmin could trigger 
elevated ILEI secretion. 
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2.2.5 Exogenous ILEI treatment   
 
We wanted to verify the result we observed in the previous experiment , namely that 
enhanced secretion of ILEI might not depend on an autocrine feedback mechanism of 
the cleaved form which would trigger its own secretion, but plasmin signalling 
independently of ILEI might upregulate the secretion.  For this, we treated the 
EpRAS cells with purified wt and mutant forms of ILEI-FLAG. After 24 hours 
incubation time conditioned media were collected and incubated with anti-Flag 
protein coupled beads to remove all exogenously added Flag tagged ILEI proteins. 
The flow through of these conditioned medium samples were loaded on an SDS-gel 
and analyzed for ILEI levels by Western-blotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 38 |   ILEI secretion levels in EpRAS cells exposed to exogenous wt and mutant 
forms of ILEI  
 
 
 
We did not observe any significant changes in secreted levels of ILEI, induced by any 
type of exogenously added purified forms of the protein, indicating that ILEI might 
not be able to initiate its own secretion. This result, however, would have to be 
confirmed by showing, that the added ILEI fractions had other biological activities 
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3. DISCUSSION 
 
The first part of this diploma thesis aimed to dissect the mechanism of proteolytic 
processing of ILEI, its influences on the secretion of the protein and its physiological 
roles on tumorigenesis. Furthermore, we studied potential connections between ILEI 
processing and secretion by challenging the hypothesis if cleaved ILEI might 
stimulate its own expression and secretion directly in an autocrine manner via 
binding to putative ILEI receptors.  
 
Cleavage of ILEI: ILEI has been found to be cleaved by plasmin at a precise position 
at its N-terminus. Nevertheless, we show here, that plasminogen knock out mouse 
serum was also able to process ILEI, indicating that in addition to plasmin other 
serine type proteases could be also involved in ILEI cleavage. Indeed, kallikrein and 
thrombin were also able to generate the short form of the protein by specifically 
cutting at the same R/S site as plasmin, however with a much lower efficiency. 
Further work will be required to clarify to what extent these other proteases 
contribute in ILEI processing under physiological conditions or whether these 
observations are only a consequence of compensatory mechanisms in the lack of the 
adequate protease, plasmin. 
 
The physiological role of ILEI processing: To address this question, in vivo mouse 
tumor xenograft assays were performed. In these experiments, we used tumorigenic 
murine breast epithelial EpC40 cells overexpressing different mutant forms of ILEI 
that were previously generated. Beside empty vector expressing control and wild 
type ILEI overexpressing (OE) cells, two additional cell lines overexpressing different 
mutant forms of ILEI were included in this study. The first ILEI mutant (FD) was no 
longer cleavable (cleavage mutant) and the other represent the mature form of ILEI, 
already lacking the pro-peptide that normally has to be cleaved off (∆pro-peptide 
mutant, ∆N). These mutant forms allowed us to examine in detail the role and 
necessity of ILEI processing in tumorigenesis and metastasis. Primary tumour 
formation ability of these cells was analysed in nude mice. wt-ILEI OE EpC40 cells 
resulted in elevated tumor growth rate and size compared to the control cells, as 
published before. (Waerner. T et al., 2006) IHC analysis of mammary tumours 
indicated that elevated tumor growth and tumor masses by overexpression of ILEI 
did not involve any alterations of proliferation and apoptotic activities. We observed 
that cleavage mutant OE cells could generate only small tumors similar to the control 
cells and ∆pro-peptide mutant OE cells formed even bigger tumors than wt-ILEI. 
Thus, ILEI derived accelerated tumour progression may require its processing. 
However, it is possible that different tumor formation abilities observed in these cells 
may occur for varying reasons, such as different secretion levels of ILEI. Indeed, in 
vitro characterization of these generated cells had differences at ILEI secretion levels, 
where cleavage mutant OE cells secreted less ILEI than wild type and ∆pro-peptide 
mutant OE cells secreted the protein at higher levels.  
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Aprotinin, a broad spectrum serine protease inhibitor, was able to inhibit ILEI 
cleavage by mouse serum in vitro in earlier studies. Thus, we could evaluate the role 
of processed ILEI in vivo, presuming that aprotinin would prevent the cleavage in 
case of the wt-ILEI OE cells in vivo as well. Thus, we could examine whether the 
generation of this short form might be essential and sufficient for an elevated tumor 
growth. Aprotinin treated mice injected with wt-ILEI OE EpC40 showed a 
significantly decreased tumor growth rate and tumor mass in compared to mice not 
treated with aprotinin, without affecting apoptotic and proliferative activity of tumor 
cells. ILEI-induced increased tumor growth was repressed in case of wt-ILEI, but not 
of delta pro-peptide ILEI mutants, indicating that aprotinin-sensitive protease 
activity was important for ILEI to generate its processed, active form. 
 
Subcellular localisation of ILEI: IHC staining for ILEI revealed localisation of the 
protein in vesicular, dot-like structures and also throughout the cytoplasm in tumors 
with higher secretion levels, like in ∆pro-peptide and wt-ILEI OE tumors. Increased 
secretion seemed to correlate with higher levels of diffuse cytoplasmic staining and 
lower levels of cells with dot-like, granular appearance of the protein. In addition, we 
observed a shift of cytoplasmic ILEI into dot-like granular structures upon aprotinin 
treatment. This may be a result of decreased secretion of the protein, however, we 
could not conclude, whether aprotinin could decrease ILEI secretion or the secretion 
could be diminished as a consequence of cleavage inhibition. Nevertheless, our fin-
ding that elevated secretion correlates with diffuse, cytoplasmic ILEI localization 
could be of major importance, because the same cytoplasmic subcellular localization 
of ILEI in a human breast cancer tissue array correlated with enhanced risk of meta- 
stasis formation and impaired survival (p-values >106 - 109, Waerner, T. et al, 2006). 
 
In vitro characterization of EpC40 tumors: Morphology of recultivated tumor cells 
overexpressing different ILEI forms was in accordance with E-cadherin and vimentin 
levels of mammary tumors analysed by IHC and also marker protein analyses of 
recultivated tumor cells by immunoblotting. In culture, cells partially kept their 
epithelioid cell structure and some patches showed also spindle shaped, 
mesenchymal like cells with the exception of the cleavage mutant, which had the 
most fibroblastoid phenotype. All types of EpC40 cells upregulated mesencyhmal 
marker proteins like vimentin and fibronectin after tumor formation in mice and 
recultivation, and downregulated epithelial proteins such as E-cadherin and ZO-1. 
However the morphological and marker results did not mirror the differences in 
tumor formation capacity of these cells, considering the cleavage mutant 
overexpressing cells having the most mesenchymal morphology, formed small 
tumors comparable to control cells. We were able to detect elevated pERK and pAKT 
levels in ∆pro-peptide mutant OE cells, which were able to generate accelerated 
tumor growth rate and tumor burden. EpC40 cells overexpress a mutated form of 
oncogenic Ras, which hyperactivates the PI3K pathway, but fails to hyperactivate the  
ERK pathway, leading to basal ERK levels in these cells. Thus, increased pERK 
signalling could result from endogenous Ras signalling that might be activated by 
the abundance of secreted ILEI. Consequently, enhanced ERK levels may be 
important for development of larger tumors and increased tumor growth rate.  
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EpC40 cells are known to signal through PI3K pathway hyperactivating pAKT 
expression and EpC40 tumors were found to retain E-cadherin expression and to lack 
the vimentin mesenchymal marker protein. (Janda et al., 2002) Nevertheless, in our 
study we found only basal pAKT expression in all EpC40 derived cells and 
downregulation of E-cadherin in EpC40 control mammary tumors was not consistent 
with this published data. Importantly, however, none of the earlier studies 
performed experiments using cells recultivated from tumors, one possibility to 
explain the observed discrepancies. 
 
Experimental metastasis assay: We tested the ability of metastasis formation of 
recultivated EpC40 ex-tumor cells overexpressing wt and mutant forms of ILEI in a 
lung colonisation assay after tail vein injection. Our data agreed with previous 
reports that EpC40- cells fail to induce EMT in vitro and metastasis in vivo. However, 
we also detected some micro metastases (1% of lung area) in control cells. As 
expected, wt and ∆pro-peptide mutant OE cells could develop metastasis at high 
rates. However, the difference at the metastatic capacity between these cells was not 
significant in overall metastatic area measurements, but the ∆pro-peptide mutant 
seemed to form fewer, but much larger metastases. In contrast, ∆pro-peptide mutant 
OE cells significantly elevated tumor growth kinetics and tumor mass compared to 
wild type in primary tumor formation assay. On the other hand, cleavage mutant OE 
cells retained a weak metastasis forming capacity, much less than wt-ILEI OE cells 
(<10% of lung area). This suggests, that basal ILEI levels would not be enough to 
generate metastases in EpC40 cells, but elevated intracellular levels of ILEI without 
having enhanced secretion of the protein, might also be able to promote metastasis. 
In line with this, another ILEI cleavage mutant with two hydrophobic phenylalanines 
(FF) replacing the wt RS site, was still able to cause full EMT in EpRas cells (Csiszar, 
unpublished). 
 
In theory, aprotinin could be a potential therapeutic tool to circumvent ILEI derived 
tumor and metastasis promotion. However, despite its ability to inhibit plasmin 
activity, aprotinin itself increases metastasis by increasing thrombosis and by 
retention of circulating cancer cells at the vascular endothelium. It has been 
published that aprotinin treatment enhances metastasis. (Turner GA., Weiss L., 1981) 
Ergo, long term exposure to aprotinin, as in ILEI-derived primary tumor formation 
experiment would be inefficient for lung colonisation assay because of its harmful 
side effects. Moreover, using of MMP inhibitors in cancer therapy had also 
disappointing outcomes. (Coussens L.M., 2002)  Thus, to circumvent the risks of using 
broad spectrum inhibitors, crucial downstream signalling molecules of these 
proteases, which might be the optimal therapeutic targets, should be identified and 
characterised. Therefore, ILEI may promise such a potential target to prevent 
invasive carcinoma.  
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In vitro secretion assays: Plasmin induces ILEI secretion in various cell lines; in 
EpRAS (tumorigenic and metastatic murine breast epithelial cells) and NIHT3T 
(mouse fibroblast cell line) and also in the human tumor cell lines HeLa and SKBR3. 
Plasmin induced ILEI secretion occurs very rapidly, within less than one hour, and at 
the same time causes a decrease of the amount of intracellular protein. Enhanced 
secretion on the cost of intracellular protein requires less than 1mU plasmin; a 
concentration which was unable to cleave all the secreted ILEI sequestered in the 
matrix. On the other hand, TGF was published as an inducer of ILEI secretion via 
upregulating ILEI translation. (Waerner T. et al., 2006) In agreement with these data, 
we found, that TGF-induced enhanced secretion occurred as a secondary step 
following enhanced translation of the protein, which took approximately 8 hours. 
Hence, plasmin’s effect on ILEI occurs via a completely different regulatory 
mechanism than TGF-stimulated ILEI secretion.  
 
Several hypotheses explaining the stimulation of the secretion are conceivable. It is 
possible that ILEI cleavage positively influences its own secretion, via autocrine 
signalling, and plasmin is needed only to generate the cleaved active form of ILEI. 
Another possibility is that plasmin may play a specific role in ILEI secretion, 
independent of ILEI cleavage, and acts through plasmin signalling. To discriminate 
between these possibilities, we tested whether plasmin, thrombin and kallikrein that 
were able to process ILEI, would enhance ILEI secretion due to the generation of the 
truncated protein. However, only plasmin triggered elevated secretion, supported by 
the finding that kallikrein failed to stimulate ILEI secretion in the absence of serum, 
while in the presence of serum, it activated plasminogen by activating the urokinase 
plasminogen activator, thus generating active plasmin to stimulate secretion. We 
conclude from these data that  ILEI does not stimulate its own secretion via an 
autocrine feedback mechanism. We confirmed this idea in experiments treating cells 
with exogenous ILEI, in which none of the purified ILEI forms could stimulate self-
secretion, not even the constitutively cleaved ∆N-ILEI.  
 
Plasmin may upregulate ILEI secretion independently of ILEI cleavage via 
plasminogen (Plg)/plasminogen activators (PA) signalling. Indeed, plasmin can 
cause intracellular effects through uPA/uPAR signalling and, as recently showed, 
also through protease activated receptor 1 (PAR1) signalling (Pendurthi U.R., 2002). In 
our experiments, this may be irrelevant, because thrombin, an activator of PAR1, 
could not affect ILEI secretion. (For details in Plg/PA signaling, see chapter 1.8).  
 
However, as suggested at the beginning, these data do not correlate with different 
secretion levels of different mutated ILEI forms being dependent on cleavability of 
the protein.  One explanation may be that intracellular ILEI stimulates upregulation 
of the Plg/PA system via regulation of expression or localisation of the system 
components, leading to its increased secretion. There is supporting data from 
expression profiling experiments, indicating upregulation of tissue plasminogen 
activator (tPA) in EpRAS-XT and urokinase plasminogen activator receptor (uPAR) 
in EpRAS-ILEI cells. (M. Jechlinger and H. Beug, unpublished).  
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Another possibility may be that the cleavage site and pro-peptide play a role in the 
regulation of ILEI secretion. A resting cell might secrete less ILEI due to the presence 
of the pro-peptide, which could be an important retention signal for the protein to 
remain intracellular or sequestered in the extracellular matrix (Bauskin A.R. et 
al.,2005), and Plg/PA signalling could release this retention through unknown 
factors. This assumption would agree with our findings in ∆N-ILEI OE EpC40 cells, 
where lack of pro-peptide led to elevated secretion; this is, however insufficient to 
explain why cleavage mutant OE cells secreted less ILEI than the wt OE cells. 
Independent data showed the significance of cleavage site sequence for the secretion. 
Thus, mutation at the cleavage site of ILEI might cause diminished recognition of 
ILEI secretion, whereas other amino acid exchanges in this cleavage site (i.e. RS to FF) 
completely inhibited ILEI secretion. (data not shown). Since this mutant was still able 
to cause complete EMT in EpRas cells, the possibility remains, that ILEI also acts via 
intracellular mechanisms.  
 
Conclusions and future perspectives: Taken together, the plasmin and plg/PA 
systems, together with the surrounding tumor microenvironment, might be the rate 
limiting factors for ILEI-derived tumor and metastasis promotion. Plasmin is 
activated by urokinase plasminogen activator (uPA), but itself is also able to activate 
uPA receptor (uPAR) bound pro-uPA. The activated complex mediates cell 
signalling through binding to several surface proteins and integrins, which may 
affect cell adhesion and migration events. In various tumor cells, uPA/uPAR and 
also integrins, for instance v3 integrin in breast cancer (Liapis et al 1996), were 
upregulated and correlated with tumor and metastasis progression. Therefore, 
plasmin dependent stimulation of ILEI secretion could be further analysed by 
inhibiting the urokinase receptor or binding sites of integrins by available antibodies 
to determine its upstream regulatory pathways. If uPAR and uPAR activated 
signalling pathways are not involved in this stimulation, it is possible that plasmin 
activates another signalling pathways via putative receptors.  
 
Mechanisms explaining ILEI-dependent tumorigenesis remain still unknown. ILEI 
secretion levels correlated with tumor progression, since ∆N-ILEI with highest basal 
secretion levels generated bigger tumors and promote larger metastases. 
Furthermore, these tumors showed increased pAKT and pERK signalling, probably 
caused through ILEI-dependent activation of endogenous Ras effector pathways via 
binding to putative receptors activating MAPK signalling and leading to EMT and 
metastasis. Also, oncogene activation in a cell may lead to elevated expression of 
ECM proteases such as plasmin and plasminogen activators. These would then 
enhance ILEI secretion, which, perhaps through downstream signalling might 
positively affect ILEI-dependent Ras signalling, thus accelerating tumor growth and 
metastasis.  
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4. PART II 
 
DOXYCYCLIN-INDUCED ILEI EXPRESSION IN MICE 
 
4.1 INTRODUCTION 
 
In recent years, several transgenic mouse strains with conditional expression of a 
gene of interest by site specific recombinases or a tetracycline/doxycycline inducible 
gene expression system have been generated. They allow to analyse the function of 
various genes and their downstream signaling pathways, thereby studying 
physiological processes and modeling the pathogenesis of human diseases. 
Tetracyclin inducible systems can provide exact temporal and spatial control of gene 
expression. It bypasses the problem that sometimes the expression of a transgene 
during early stages of the development or in organs where it is normally not 
expressed can be detrimental because of lethality or toxicity. Further, the system is 
reversible and specifically induced by exogenous non-toxic agents in a dose 
dependent fashion, enabling an independent regulation of targeted gene from 
cellular pathways. (Jaisser F., 2000) 
 
The tetracycline inducible system is based on the mechanism of tetracyclin resistance 
in E.coli. Tetracyclin repressor (TetR) binds on the regulatory elements of the tn10-
specified tetracyclin-resistance operon of E. coli and negatively regulates the resist-
ance-mediating genes. In the presence of the antibiotic tetracyclin or its derivatives 
(eg Doxocyclin; Dox) tetR cannot bind to its operators and transcription can occur. 
This system was described first by Gossen and Bujard et al. (1992). Then they modified 
the original E.coli tet repressor (TetR) with the activating domain of virion protein 16 
of herpes simplex virus and generated a tetracycline-controlled transactivator (tTA), 
which is expressed constitutively. Using random mutagenesis, a mutant form of 
modified tTA has been isolated. This mutant named reverse tTA (rtTA), is expressed 
upon exposure to the antibiotic, which is opposite to tTA in that it is functional in the 
absence of tetracyclin and its derivatives.  
 
The system consists of two components: a tetracycline-controlled transactivator 
regulatory component (tTA or rtTA) and a response construct with a tTA/rtTA 
dependent promoter that regulates the expression of the gene of interest. In the 
presence of tetracycline or doxycycline (Dox), tTA cannot bind to the tet operator and 
transcription fails, therefore this system is termed as Tet-OFF. A mutant form of tTA 
termed rtTA binds to its operator after doxycycline induction, allowing transcrip-
tional activation of a gene of interest only in response to varying concentrations of 
doxycycline. This system is termed as Tet-ON. (Gossen and Bujard, 1995) 
 
      For reduced basal activity and increased Doxcycline sensitivity, modifications and 
improvements has been made on the rtTA protein by Urlinger et al. (2000). This has 
helped to overcome some of its limitations, like inefficient doxycycline response in 
some organs and residual affinity of rtTA to tetO in the non-induced state, which had 
originally led to enhanced background activities of the transgene. 
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Random integration of these elements into the genome may involve some 
disadvantages, like disruption of endogenous genes  or position variegation effects. 
Therefore, these elements should be introduced by homologous recombination. 
(Beard et. al., 2006) 
 
      In this diploma thesis, a TET-ON mouse transgenics system was used, generated by 
the frt/flpase strategy in ES cells by the laboratory of Mathias Müller, VMU Vienna, 
adapted from Caroline Beard et al.(2006). This system provides efficient targeting of 
inducible transgenes to a specific locus and is generated in two steps. First, site 
specific integration of a doxycycline responsive element TetOP controlling the gene 
of interest was targeted downstream of the collagen 1a1 locus, which has shown a 
high transgene expression profile in all cell types. This insertion element  contains frt 
sites downstream of the promoter enabling the recombination and inducible 
expression of any desired genes after a flpase reaction. In the second step the 
modified M2 reverse tetracycline transactivator (M2-rtTA) is targeted into the 
ROSA26 locus (ROSA26::rtTA). High expression of M2rtTA from the endogenous 
ROSA26 promoter has been found in all tissues and cell types except in brain and 
testis, resulting in highly efficient and ubiquitous expression of the transactivator. 
(Beard et. al., 2006) 
 
      In this study transgenic mice were characterized where a C-terminally FLAG tagged 
version of the ILEI transgene was introduced into the Col1A1 locus. Two sets of mice 
were used. One group was engineered to express both the M2rtTA constitutively 
from the ROSA26 locus and a doxycyclin responsive element controlling ILEI-FLAG 
gene, targeted into the collagen 1A1 locus by frt/Flpase mediated site specific 
integration. I will refer to this group as double transgenics. In addition, single 
transgenic mice were taken as control animals, expressing only the M2rtTA and 
lacking the ILEI transgene to examine the background activity of the transactivator 
with doxycyclin. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 39    Left panel: Repression of gene expression in the presence of the tetracycline  
            analogue doxycyclin (TET-OFF) 
                         Right panel:  Gene expression in the presence of dox. by binding to the 
                        mutated Tet-on regulator (rTetR) (TET-ON) 
                        The VP16 transcriptional activation domain (VP) is derived from the herpes  
           simplex virus gene encoding the VP16 protein  
   Ref.:http://www.biochem.arizona.edu/classes/bioc471/pages/Lecture15/Lecture15.html 
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4.2 RESULTS  
 
Inducibility of ILEI upon doxycyclin exposure in our generated mice was tested in 
several organs. ILEI levels were analyzed by using Western blotting and 
immunohistochemistry. Doxocyclin was given to the mice in the drinking water. 
 
 
4.2.1 ex-vivo Test of ILEI inducibility with doxycyclin  
 
2,5x106 of  primary bone marrow and spleen cells isolated from double and single 
transgenic mice were  plated out and treated with different amount of doxycyclin for 
the time indicated (FIGURE 40). Thereafter, the cells were lysed and analyzed for 
ILEI expression levels by immunoblotting. 
 
 
 
 
 
                          
         conc. µg/ml    -     0,2   1     5     5      -    0,2   1     5     5 
 
 
 
 
 
        
 
 
                                    
FIGURE 40    Intracellular ILEI levels of spleen and bone marrow cells exposed or not  
                        exposed to doxycylin  
 
 
We have detected elevated ILEI expression levels both in spleen and bone marrow 
within 24 or 48 hours upon the addition of 1 to 5 µg/ml of dox. Additionally, we 
could specifically detect induced exogenous ILEI with -Flag M2 antibody. We could 
observe endogenous ILEI expression in the spleen, but not in the bone marrow.  
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4.2.2 In vivo Test   
 
We treated two double transgenic mice with 1 mg/ml of doxycyclin provided in the 
drinking water (supplemented with 5% sucrose) for 3 days. As controls, two 
additional double transgenic animals were kept on sucrose-supplemented drinking 
water without doxycyclin for the same time. After sacrificing the mice, we isolated 
several organs for further analysis. Spleen, bone marrow and blood sera were 
examined by immunoblotting for exogenous ILEI expression levels. Other organs, 
e.g. lung, intestines, liver, kidney and skin were fixed in 4% para-formaldehyde and 
analyzed by immunohistochemistry using ILEI and Flag antibodies.    
 
 
 
                                 -Dox          +Dox              -Dox            +Dox 
                               M1   M2     M3    M4        M1       M2    M3    M4             
                        
  
 
 
 
 
 
 
 
                                              anti-ILEI                          anti-FLAG 
 
FIGURE 41 |   ILEI expression of spleen-, bone marrow- and peripheral blood cells from 
transgenic mice treated or not treated with Dox 
 
 
 
We obtained similar results as in the ex vivo pilot experiment. ILEI levels were 
increased both in spleen and bone marrow in mice treated with 1mg/ml dox. for 72 
hours. Moreover we detected a high induction of ILEI expression in blood sera.  
FLAG bands in –Dox spleen may be the result of tissue dependent unspecific binding 
of the antibody. 
We have detected endogenous ILEI expression in small and large intestines and in 
kidney tubuli. Liver, skin and lung did not show any endogenous ILEI expression by 
immunostaining. Doxycyclin induced elevated ILEI expression in all investigated 
tissues except lung. In the lung, clara cells were detected as expressing ILEI after 
doxycyclin treatment. The epidermal layer of the skin and the cells of the hair 
follicles likewise showed ILEI expression upon doxycyclin induction (FIGURE 42). 
The highest ILEI levels after doxycyclin exposure were found in the villi of the large 
and small intestines. (FIGURE 43)  
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Interestingly, the exogenous, Dox-induced ILEI detected by anti FLAG antibodies 
showed the typical subcellular localization of ILEI in normal epithelial cells, i.e. 
rather large, granular structures apical of the nuclei, i.e. the position of the Golgi 
apparatus. This was true for kidney tubules (FIGURE 42) and small- and large 
intestine epithelia (FIGURE 43). It was remarkable, that tissues lacking expression of 
endogenous ILEI also expressed no or low levels of exogenous FLAG-ILEI, 
suggesting tight regulation of already synthesized ILEI  by posttranslational 
mechanisms, e.g. protein degradation. 
 
 
 
 
 
                                    
      
  
FIGURE 42 |   ILEI and Flag IHC staining of several organs with/out doxycyclin treatment 
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FIGURE 43 |   ILEI&Flag IHC staining of small and large intestines of mice 
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4.3 DISCUSSION 
 
An ILEI transgenic mouse strain by using the Tet-ON system inserted via the flp-in 
strategy has been generated successfully and these animals showed a specific, 
doxycyclin-responsive increase in ILEI expression in vivo without basal activity of 
the transgene in a non-induced state.  
 
We could conclude that large and small intestines and kidney showed endogenous 
ILEI and elevated expression of the protein after induction as well. We detected good 
doxycyclin responsive expression in the skin and in the liver, however these tissues 
showed no endogenous ILEI expression. We did not observe any endogenous or 
induced ILEI in the lung, even after doxycyclin treatment. 
Using the same transgenic strategy, which we adapted from Beard et al., these 
authors have observed EGFP expression in all tissues and all cell types, except for the 
absence in brain, testis and skeletal muscle. They suggested that the lack of 
expression in brain and testis might be due to the inability of doxycyclin to cross the 
blood-testis/brain barriers. In a separate study, using the same strategy, similar 
expression patterns of oct4 gene have been reported. (Hochedlinger et. al., 2005) 
Although the Rosa26 promoter results in ubiquitous and broad expression of 
transgene, we observed induced expression of ILEI not in all tested tissues. In 
addition, we detected lack of endogenous ILEI in the lung by immunostaining and in 
spleen by Western blotting. Nevertheless, ILEI (FAM3C) mRNA expression has been 
examined almost in all tissues, including lung and spleen by using Northern blot 
analysis (Zhu et. al., 2002). Since the translational control of ILEI expression is also 
known (Waerner et. al., 2006), tissue specific mRNA levels of ILEI after induction by 
RT-PCR or Northern blot should be checked, to clarify this contradiction. 
 
This transgenic mouse model will now allow studying the physiological role of ILEI 
as well as its role on tumor progression and metastasis by the induction of stable ILEI 
expression in adult mice with or without other tumorigenic effectors in different 
tumor assays. 
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5. MATERIALS and METHODS  
  
5.1 Cell Culture 
 
Cells used in this study Cell Culture Medium  
EpRAS, EpC40, SKBR3, Hela, MCF7 Eagle (house made in media kitchen) 
supplemented with 10% FCS, 1U/ml 
Penicilin, 1µg/ml Streptomycin, 20mM 
HEPES and 2mM L-Glutamin 
NIH3T3* Dulbecco’s Minimal Essential Medium 
(DMEM) supplemented with 10% FCS, 
1U/ml Penicilin, 1µg/ml Streptomycin, 
20mM HEPES and 2mM L-Glutamin 
  
* NIH3T3 cells were treated with 1x Trypsin instead. 10xTrypsin was diluted with 1x 
PBS 1:10.  
 
 
5.1.1 Generation and splitting of adherent cells 
 
Cells were grown on plastic Petri dishes with indicated media at 37°C in cell culture 
incubators containing 5% CO2. At confluency, they were splitted out to enable cells 
further growth. If they could not grow enough up to confluency, the media should be 
changed in every 2 days. For splitting, conditioned medium was removed, cells were 
washed once with 1x PBS and detached from dishes with 10x Trypsin (1 ml for a 
10cm Petri dish) at 37°C for ~2-5’. Trypsin was inactivated with FCS containing 
medium, cells were resuspended and diluted in fresh medium appropriately to their 
proliferation capacity and seeded again in new dishes.  
 
Cells were frozen to -80°C gradually and then kept at -270 in liquid nitrogen for long 
time. For freezing trypsinized cells were centrifuged for 5’ at 1200rpm, pellets were 
suspended in FCS supplemented with 10% DMSO (1ml FCS for cells from a 10cm 
confluent Petri dish). Then they were transferred in cryogen micro tubes (Nalgene) 
and frozen. Thawing of these cells were performed quickly in a 37°C water bath, 
fresh media added to dilute DMSO and they were spinned down. After removing 
toxic DMSO, which is harmful for cell membranes, cells were given in fresh media 
and plated out. 
 
 
 
5.1.2 ILEI Secretion Assay 
 
400.000-700.000 cells were plated out with 3 ml of appropriate medium in 6-well 
plates. Once they were adherent medium was changed with 1 ml starvation* 
medium or medium with 4% FCS and exogenous treatments e.g. with TGFb or 
plasmin, if any, were administered. After 24 hour incubation time conditioned media 
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were collected and the cells were trypsinized, harvested and counted with cell 
chamber. Cells were centrifuged for 5’ at 1200rpm and cell pellets were washed once 
with 1xPBS to remove rest of the medium.    
* Starvation medium lacks FCS, as a replacement of high protein content the medium 
was supplemented with 0,1% BSA (sterile filtered). 
 
 
5.1.3 Isolation and cultivation of primary spleen and bone marrow cells from mice 
 
Dissected tibia and femurs of mice were cut off at both ends and the inner part of leg 
bones were rinsed out with a syringe with 1x PBS and the bone marrow was 
collected. Spleen were minced, suspended in PBS, filtered and centrifuged at 
1200rpm for 5 min. PBS was removed and the cells were plated out in plastic culture 
dishes with Dulbecco’s Minimal Essential Medium (DMEM) supplemented with 10% 
FCS, 1U/ml Penicillin, 1µg/ml Streptomycin, 20mM HEPES and 2mM L-Glutamine. 
Indicated amounts of Doxycyclin were given to the culture medium for 24 or 48 
hours. 
Then they were suspended and collected and centrifuged for 5’ at 1200rpm and the 
media were discarded. The cell pellets were washed again with 1xPBS to remove rest 
of the medium.  
 
 
5.1.4 Isolation and re-cultivation of tumor cells 
 
Excised tumors from mice were minced and incubated in EAGL 10% FCS 
supplemented with 2,5 mg/ml collegenase type I (Sigma) for at least 2h at 37°C. 
Digested tissues were suspended with pipette tips, filtered through nylon cell 
strainers (70µm, BD Falcon) to remove large particles, centrifuged and washed with 
1x PBS. Then they were plated out for recultivation in Eagle 10% Medium treated 
with G418 sulphate antibody (Gibco Geneticin 800µg/ml) to select tumor cells and 
with amphotericin B (Biochrom AG stock 250µg/ml diluted in 5ml sterile aqua 
distilled) to protect cells from fungi and yeast.  
 
 
 
5.1.5 In vitro ³H Thymidin proliferation assay 
 
Cells were plated out as triplets in a 12 well/plate and incubated for 24 hours. Next 
day they were labeled for 2 hours by adding 30µCi/ml methyl ³H Thymidin (TRK 
120) to the media. After removing radioactive media eloboratively, cells were treated 
with 30µl 10x Trypsin/well and 150µl 1xPBS was added. Samples were transferred 
then onto a filter mat (90x120mm) with Tomtec harvester. The filter was put wax on 
and dried in a microwave oven (max. 60°C) till the wax melt homogenously. The 
prepared samples were read in a 1450 Micro beta liquid scintillation counter 
(Wallac). Results were normalized to the cell numbers. 
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5.2 Protein Chemistry 
 
5.2.1 Determination of protein concentration with Bradford reagent 
 
BSA stock solution with 1mg/ml concentration was used to prepare a 2,5- 10µg/ml  
standard concentration series. The standards and 1µl of protein samples were mixed 
thoroughly in plastic cuvettes with 1ml Bio-Rad Bradford solution, which was pre-
diluted 1:5 in distillated water. The extinction at 595nm was measured in 
spectrophotometer. 
 
 
5.2.2 Preparing of whole cell lysates for SDS gels  
 
The cell pellets were lysed with 60-100µl lysis buffer incubating them for at least 30’ 
on a rotator at 4°C and after that they were centrifuged at full speed for 20’ at 4°C. 
The supernatants (cell lysates) were collected in fresh tubes and protein 
concentrations were measured using Bradford assay.  
Ingredients of the lyses buffer: 10% Glycerol 
                                            50 mM HEPES pH 7,5 
                                            150 mM NaCl 
                                            0,5% T-X100 
                                            1,5 mM MgCl2 
                                            1 mM EGTA 
                                            200µM Na3VO4 
                                            10 mM NaF 
 
 
5.2.3 Concentration of supernatant (conditioned medium) for SDS-PAGE 
 
Collected supernatants (~1ml) were concentrated (ultra-filtration) before running an 
SDS-PAGE. Supernatants were transferred into Ultracel YM-10 filters with a nominal 
weight limit of 10kDa, placed in Microcon centrifugal filter device and centrifuged 
for ~50’ at 14000g at 4°C. All proteins under 10kDa and medium were collected in the 
tube and discarded. The filter with concentrated proteins bigger than 10kDa (also 
ILEI 26kDa) were flipped up side down in a fresh tube and centrifuged for 2’ at 
10000rpm. The concentrated volumes of supernatants were determined with a 
pipette and the amounts (conditioned Medium from ~1-2x105 cells) to be loaded onto 
an SDS gel were normalized to the cell numbers.  
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5.2.4 In vitro ILEI cleavage Assays 
 
Cleavage of different mutant and wt ILEI proteins by proteases or sera was done 
using proteins purified from cells overexpressing these ILEI forms. Appropriate 
amount of proteins was put into a tube with indicated proteases or sera or protease 
inhibitor and incubated for 5-10 hours at 37°C in an incubator. They were loaded 
then on SDS-PAGE to detect cleaved and non-cleaved ILEI. 
 
 
5.2.5 Immunoprecipitation (IP) of Flag epitope tagged proteins 
 
Anti Flag M2 Agarose Beads (Sigma) were used for IP of different mutant ILEI-Flag 
proteins over expressing in EpRAS cells. The beads were already conjugated with 
Flag antibodies and there was no need for binding and cross linking of antibodies to 
the beads. The beads were pre-eluted 1x with 10 bed volumes (bv) 0,1 M glycin,  
pH 2 and washed 3x briefly with 10 bv 1xTBST* to re-equilibrate. We standardized 
amount of beads and proteins for an efficient binding and elution. Therefore 0,7mg 
protein from whole cell lysate (or supernatant) was incubated with 20µl of beads 
over night at 4°C on a rotator. Next day they were centrifuged for 2’ at 1000g at 4°C 
(beads are sensitive and should not be centrifuged higher than 1000g), supernatants 
were discarded. (They could be collected to see if the binding of antibodies to the 
proteins were sufficient). Pelleted beads were washed then 3x with 10 bv ice-cold IP-
buffer** each for 10’ at 4°C. Then they were washed 2x with 150mM NaCl to remove 
pH-buffering agents and protease inhibitors. For the elution 25µl 0,1 M glycin (pH 2) 
were added to the beads, mixed for ~2’ and centrifuged 2’ at 1000g at 4°C and 
supernatant was transferred in a fresh tube. This elution step was repeated one more 
time. The beads should not be incubated with glycin pH 2 longer than 10’, therefore 
after elution they were washed 3x with 10 bv TBST to recover. To neutralise the 
eluate 1,5 M Tris-HCl, pH 9,2 ( 5µl Tris per 100µl eluate) was added and solution was 
tested with pH paper. (It should be approx. 7-8) 
  
* TBST: 1x TBS + 0,04% Triton X-100 
** IP-buffer: 20mM Tris-HCl, pH 7,5, 150mM NaCl, 10% glycerol, 2mM EDTA, 
0,5mM TritonX-100 
Plus phosphatase inhibitors: 20mM β-glycerophosphate, 10mM NaF, 5mM Na-
pyrophosphate, 1mM Na-vanadate, 2mM EGTA 
No protease inhibitor cocktail was added to the eluate because the eluates were then 
used in ILEI cleavage assays.   
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5.2.6 SDS PAGE  
 
10% SDS Gel was prepared with 1 or 1,5mm thickness. 25µg/ml protein of each 
sample was mixed with 1x loading buffer, boiled 5’ at 95°C and loaded on 10% SDS 
gels.  
 
 Stacking Gel: (10%) 
 
Running Gel: (10%)  
 
 Stacking gel buffer (0.5 M 
Tris, pH 6.8 0.4% SDS) 625µl 
Running gel buffer (1,5M 
Tris, pH 8.8) 2.5 ml 
30% AA/Bis 
Solution (BioRad)  
3.22 ml 675 µl 
dH2O  2.89 ml 3,7 ml 
10% AMPS  55µl 30µl 
TEMED  5,5µl 12,5µl 
 
Composition of loading buffer (4x): 200mM TrisHCl, pH 6,8; 8% SDS, 0,4% 
Bromphenol Blue (BPB), 20% Glycerol, 10% 2-Mercaptoethanol 
The gel was run with 1xPAGE running buffer (0.025 M Tris base, 0.2 M Glycine, 3,5 
mM SDS) at 200V for 1 hour. 
 
 
5.2.7 Semi-dry Western blot analysis 
 
The proteins from SDS gel to PVDF membrane were transferred by semi-dry Western 
blotting. Thereby, two filter papers Watman 3MM and the gels were soaked into 
semi-dry transfer buffer, PVDF membrane was activated first in methanol then 
soaked into blotting buffer to equilibrate and then the blotting sandwich was put 
together from bottom-to-top Filter paper – membrane – gel – filter paper.   
Blotting was performed at 60mA for each gel (with a size of 6,5cm x 8,5cm 
corresponding to 1mA/cm2) for at least 1,5 hours at room temperature. Then the 
membrane was blocked with 5% milk in 1xTBST* at room temperature for an hour or 
over night at 4°C . After blocking it was incubated with desired 1st antibodies for  at 
least 1 hour at room temperature or over night at 4°C, washed 3x with 1xTBST and 
then incubated with horse radish peroxidase-coupled secondary antibodies (1:5000) 
for 1 hour at room temperature or over night at 4°C and washed again 3x with 
1xTBST. For the detection of the desired protein the membrane was incubated with 
the ECL or ECL plus chemoluminescence reagents and a high performance 
chemoluminescence film was put on it in dark room. After an efficient lightening 
time the film was developed. 
* TBST: 1x TBS (150 mM NaCl, 7,7mM TrisHCl); 0.1 % Tween20 
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5.2.8 Stripping of Western Blot membrane 
 
To stain the same Western Blot membrane with another 1st antibody, the membrane 
was stripped for 20’ at 55°C shaking in stripping buffer*. It was washed then 
generously with 1xTBS-T and blocked again, afterwards the same western blot 
protocol was applied. 
* Stripping buffer: 2% SDS, 62,5 mM Tris-HCl, 144 mM β Mercaptoethanol pH 6,7 
* ILEI, Flag and phosphorylated antibodies were sensitive against stripping of blots. 
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5.3 Mouse work 
 
5.3.1 Mice used in these experiments 
 
The bloods were collected from Plg-/- and wild type mice with BL6 background. 
Doxycyclin induced ILEI overexpressing system was tested also in BL6 mice. 
Mammary gland fat pad and tail vein injections of tumor cells were performed in 
NMRI nude mice.  
 
 
5.3.2 Mammary gland fat pad injection of EpC40 cells overexpressing different 
ILEI mutant forms 
 
Mice were injected intraperitoneally with an anesthetic (0,2 ml per 10g of body mass) 
containing Ketamin (5 mg/ml) and Xylazine (0,8 mg/ml). Once they were 
anesthetized, 2*105 of desired cells in 30µl 1xPBS were injected into 3rd and 4th pairs 
of the fat pads of mammary glands. Growing tumors were measured weekly with a 
caliper and the tumor volumes were calculated. (Tumor volume = (width2 
*length)/2)  
 
 
5.3.3 Tail vein injection of re-cultivated tumor cells 
 
Per mouse 2*105 cells suspended in 200µl 1x PBS were injected into the tail vein to 
analyze the lung colonization capability of tumor cells overexpressed different 
mutant forms of ILEI. 
 
 
5.3.4 Administration of Doxycyclin 
 
1mg/ml Doxycyclin supplemented with 5% Sucrose were given into drinking water 
of mice.   
 
 
5.3.5 In vivo Aprotinin treatment  
 
100µl of 4000 KIU Aprotinin (Roth Karlsruhe) dissolved in 0,9 % NaCl (sterile 
filtered) was injected intraperitoneally into the mice every day. 
 
 
5.3.6 Extraction of sera 
 
Collected bloods from mice were centrifuged for 10’ at 6000rpm to pull down all 
blood components like white blood cells and erythrocytes. Then sera were taken out 
in fresh tubes. 
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5.4 DNA Techniques 
 
5.4.1 Isolation of genomic DNA from mouse tail 
 
2mm tail or fingers of ~2 weeks old mice were cut, 400µl tail buffer* and 0,5 mg/ml 
Proteinase K added and incubated ON at 55°C.  Next day they were mixed for 5’ on 
Eppendorf mixer, added 133µl conc. NaCl (~6M), mixed again 5’ and centrifuged 10’ 
full speed. Upper part without top phase and pellet was given into a fresh tube and 
350µl isopropanol was added, mixed 2’ on eppendorf mixer and spinned 2’ at full 
speed. Supernatant was discarded and pellet was washed with 300µl 70% Ethanol. 
Pellet was dried then in open tubes and dissolved in 50-150µl TE** incubating for 2 
hours at 37°C with occasionally shaken on the Eppendorf mixer.  
 
* Tail buffer: 50mM Tris-HCl pH8, 100mM EDTA, 100mM NaCl, 1% SDS 
**TE buffer: 10mM Tris/HCl, 1mM EDTA pH8 
 
 
5.4.2 Polymerase Chain Reaction (PCR) 
 
25µl of reaction were prepared with 2µl DNA, 1µl primer mix (10mM each), 22µl 
ddH2O and PCR beads.  
The program was started with initial denaturation step at 94°C for 3’. 
In the first setup there were 19 cycles comprising of a short denaturation step at 94°C 
for 20’’, an annealing step at 64°C (-0,5° per cycle) for 30’’, an elongation step at 72°C 
for 35’’ (approx. 1’ for 1kb). The second setup of 24 cycles was performed as the 
following: 94°C for 20’’, 54°C annealing temperatur for 30’’ and 72°C for 35’’. 
Reaction was ended up with an elongation step at 72°C for 5’ and terminated at 4°C. 
Loading buffer (Orange G) was added to the samples and loaded onto an agarose 
gel. 
 
 
5.4.3 Agarose gel electrophoresis 
 
The size of separated DNA fragments depends on the Agarose concentration varying 
between 1-2%. Agarose was suspended in 1x TAE buffer and dissolved completely in 
microwave. After cooling down 10mg/ml ethidium bromide was added and the mix 
was poured into a gel tray and gelatinated. The gel was put then in a gel chamber 
containing 1x TAE and run at 100 mA.  
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5.5 Histology 
 
5.5.1 Preparation of frozen tissue sections 
 
Tumors from mice were washed once with 1xPBS, embedded in Tissue-Tec O.C.T. 
and frozen at -80°C. Frozen blocks were cut in 12µm sections with the Cryostat. 
Slides were dried for 30’ at RT and then stored at -20°C for IHC staining. 
 
 
5.5.2 Preparation of PFA-fixed and paraffin embedded tissue sections  
 
The dissected tissues were fixed in 4% PFA for at least 24 hours and dehydrated in 
Tissue-Tek VIP machine. Then they were embedded in hot paraffin. After they were 
solid 2µm sections were cut with a microtome and taken on super frost+ glass slides. 
Before staining, slides were dried at 55°C over night. 
 
 
5.5.3 Staining of PFA-fixed and paraffin embedded tissue sections 
 
 
5.5.3.1 Hematoxylin and Eosin staining (H&E) 
The staining was performed in the Thermo Scientific Microm HMS 740 Robot Stainer 
at RT.  
 
 
5.5.3.2 ILEI & FLAG immunohistochemistry 
 
After slides were deparaffinizied they were boiled for 20’ in antigen retrieval buffer 
(DAKO, citrat buffer pH6) to unwind the antigen surfaces within the tissues. Then 
they were cooled down for 20’ in the buffer and washed with 1xPBS for 8’. The 
following drop reactions were performed in a wet chamber: 
Blocking of unspecific binding sites with goat serum* for 15’ 
Addition of the first antibody diluted in 1% BSA/1xPBS for at least 1 hour  
(anti rabbit anti ILEI 1:1000, pre-incubated with homologous peptides FAM3A and D 
8ng/ml ON at 4°C) 
Wash 3x with 1xPBS for 2’ 
Blocking of endogenous peroxidase with 0,3% H2O2 in 1xPBS for 20’ 
Wash 3x with 1xPBS 2’ 
Addition of secondary antibody in 1% BSA/1xPBS for 30’ 
(biotinylated goat anti rabbit 1:500) Wash 3x with 1xPBS 2’ 
Incubation with streptavidin-biotin complex for 30’ at RT (Vectastain Vector ABC 
Kit)  
( 10µl solution A is mixed with 1ml 1xPBS then 10µl solution B added and this was 
incubated for 30’ at room temperature after that 1ml 1xPBS and 20µl goat serum was 
added in the reaction 
Wash 3x with 1xPBS 2’ 
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Color development in AEC** solution for 8’ 
Wash with H2O 
Counterstain with hematoxylin (1g/L) for 3’’, wash in H2O  
Incubate in 0,16% HCl for 2’’ for weakening strong signals 
The slides were then dried at RT and mounted with Aquatex solution. 
 
* goat serum blocking solution: 2% goat serum, 1% BSA, 0,1% cold fish gelatin, 0,1% 
TritonX-100, 0,05% Tween20, 0,05% sodium azide, 1xPBS, pH7,2; stored at 4°C 
**AEC stock solution was 3,3,amino-9-ethyl carbozole dissolved in 100ml N,N-
dimethyl form amid. For working solution 7ml of AEC stock solution were added in 
200ml sodium-acetate buffer (20mM, pH=4,9) and filtered. Finally 22µl H2O2 (30%) 
were added.  
 
 
5.5.3.3 IHC Stainings for Casp3, Ki67 and F4/80 
 
The stainings were done by Histolab similar to a standard IHC protocol except 
applying an instrument (IHC Kits) to strengthen and amplify the signal. IHC 
reagents to optimize the staining for each antibody are listed below: 
 
1st Antibody provider Type dilution instrument Antigen 
retrieval 
Caspase 3 Cell 
signaling 
Rabbit 
monoclonal 
1:100 Omni Map 
Dab anti-Rb 
Dako 
Ki67 Novo castro Rabbit 
monoclonal 
1:1000 Dab Map Dako 
F4/80* ABDSerotec  Rat 
antimouse 
1:100 Dab Map Citrat pH6 
 
* After boiling in antigen retrieval Buffer, slides were incubated and blocked in 4% 
milk buffer for 1 hour. Slides were incubated with 1st and 2nd antibodies for 1 hour 
each.  
 
5.5.3.4 IHC stainings for E.cadherin, Vimentin and Flag  
 
IHC stainings with anti-mouse antibodies on mouse tissues result high background 
staining, which then obscure the specific staining. This problem was eliminated by 
using M.O.M Immunodetection Kit (Vector). M.O.M Kit procedure was performed 
with the following mouse monoclonal antibodies:  
 
 provider Dilution Retrieval buffer 
E.cadherin BD Transduction 1:800 Dako 
Vimentin Sigma (clone 13.2) 1:500 Tris/EDTA* pH9 
Flag M2  Sigma 1:500 Dako 
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5.5.3.5 IHC staining for CD31 antibody  
 
Prepared frozen tissue sections were fixed 10’ at 4°C with acetone, washed 3x in 
1xPBS. Then endogenous proxidase was inhibited 20’ with 0,3% H2O2/1xPBS. The 
sections were washed again 3x with 1xPBS and the standard IHC protocol, just 
described above, was followed. Slides were stained with 1st antibody CD31 ( rat anti 
mouse, BD Pharmingen, 1:50) and with 2nd antibody polyclonal biotinylated anti-rat 
antibody. (Dako) 
 
 
5.6 Microscopy 
 
5.6.1 Light microscopy  
 
Pictures of IHC stained tissues were taken by Axioplan 2 imaging from a Zeiss 
microscope with Image Access software. 
H&E stained lung tissues were scanned with a Zeiss scanner (Mirax) for lung 
metastasis analyses and representative images were taken with Zeiss Mirax viewer 
software.  
 
 
 
5.7 Statistical Analysis 
 
5.7.1 Statistical significance 
 
It was evaluated by estimating two-tailed Student’s T-test. P values under 0,05 were 
considered as significant.  
 
 
5.7.2 Analysis of metastatic lung area 
 
PFA fixed and paraffin embedded lungs were cut with a microtome, generating 2µm 
sections at 300µm intervals. ~9-11 sections per mouse were stained with Hematoxylin 
and Eosin. They were scanned then with the Zeiss Mirax scanner, whereby the actual 
analyses could be performed by Definiens Analyst software. All sections were 
worked on for metastatic and whole lung areas. Analysed areas from serial sections 
of one lung were added then and the percentage of metastatic area was calculated.     
 
 
5.7.3 Evaluation of IHC Stainings 
 
For evaluation of Ki67 and actCasp3 stainigs of primary tumor tissues, 3 different 
representative images per tumor were chosen, the numbers of positive and negative 
nuclei were counted and the percentage of stained positives cells were calculated. 
 
 90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 91 
REFERENCES 
 
1. Akhurst, R. J. and R. Derynck (2001). "TGF-beta signaling in cancer--a double-
edged sword." Trends Cell Biol 11(11): S44-51. 
2. Andreasen, P. A., L. Kjoller, et al. (1997). "The urokinase-type plasminogen 
activator system in cancer metastasis: a review." Int J Cancer 72(1): 1-22. 
3. Andreasen, P. A., R. Egelund, et al. (2000). "The plasminogen activation 
system in tumor growth, invasion, and metastasis." Cell Mol Life Sci 57(1): 25-
40. 
4. Arora, P., T. K. Ricks, et al. (2007). "Protease-activated receptor signalling, 
endocytic sorting and dysregulation in cancer." J Cell Sci 120(Pt 6): 921-8. 
5. Bauskin, A. R., et al. (2005). "The propeptide mediates formation of stromal 
stores of PROMIC-1: role in determining prostate cancer outcome." Cancer 
Res. 15;65(6):2330-6.  
6. Beard, C., K. Hochedlinger, et al. (2006). "Efficient method to generate single-
copy transgenic mice by site-specific integration in embryonic stem cells." 
Genesis 44(1): 23-8. 
7. Bergers, G. and L. M. Coussens (2000). "Extrinsic regulators of epithelial tumor 
progression: metalloproteinases." Curr Opin Genet Dev 10(1): 120-7. 
8. Berx, G., E. Raspe, et al. (2007). "Pre-EMTing metastasis? Recapitulation of 
morphogenetic processes in cancer." Clin Exp Metastasis 24(8): 587-97. 
9. Blasi, F. and P. Carmeliet (2002). "uPAR: a versatile signalling orchestrator." 
Nat Rev Mol Cell Biol 3(12): 932-43. 
10. Borgono, C. A. and E. P. Diamandis (2004). "The emerging roles of human 
tissue kallikreins in cancer." Nat Rev Cancer 4(11): 876-90. 
11. Bugge, T. H., L. R. Lund, et al. (1998). "Reduced metastasis of Polyoma virus 
middle T antigen-induced mammary cancer in plasminogen-deficient mice." 
Oncogene 16(24): 3097-104. 
12. Campbell, P. M. and C. J. Der (2004). "Oncogenic Ras and its role in tumor cell 
invasion and metastasis." Semin Cancer Biol 14(2): 105-14. 
13. Cantley, L. C. (2002). "The phosphoinositide 3-kinase pathway." Science 
296(5573): 1655-7. 
14. Carmeliet, P. and R. K. Jain (2000). "Angiogenesis in cancer and other 
diseases." Nature 407(6801): 249-57. 
15. Castellino, F. J. and V. A. Ploplis (2005). "Structure and function of the 
plasminogen/plasmin system." Thromb Haemost 93(4): 647-54. 
16. Chaudhury, A., G. S. Hussey, et al. (2010) "TGF-beta-mediated 
phosphorylation of hnRNP E1 induces EMT via transcript-selective 
translational induction of Dab2 and ILEI." Nat Cell Biol 12(3): 286-93. 
17. Coussens, L. M., B. Fingleton, et al. (2002). "Matrix metalloproteinase 
inhibitors and cancer: trials and tribulations." Science 295(5564): 2387-92. 
18. Cui, W., D. J. Fowlis, et al. (1996). "TGFbeta1 inhibits the formation of benign 
skin tumors, but enhances progression to invasive spindle carcinomas in 
transgenic mice." Cell 86(4): 531-42. 
 92 
19. Curino, A., D. J. Mitola, et al. (2002). "Plasminogen promotes sarcoma growth 
and suppresses the accumulation of tumor-infiltrating macrophages." 
Oncogene 21(57): 8830-42. 
20. De Wever, O. and M. Mareel (2003). "Role of tissue stroma in cancer cell 
invasion." J Pathol 200(4): 429-47. 
21. Derynck, R., R. J. Akhurst, et al. (2001). "TGF-beta signaling in tumor 
suppression and cancer progression." Nat Genet 29(2): 117-29. 
22. Dublin, E., A. Hanby, et al. (2000). "Immunohistochemical expression of uPA, 
uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong 
associations with tumor pathology." Am J Pathol 157(4): 1219-27. 
23. Egeblad, M. and Z. Werb (2002). "New functions for the matrix 
metalloproteinases in cancer progression." Nat Rev Cancer 2(3): 161-74. 
24. Elenbaas, B. and R. A. Weinberg (2001). "Heterotypic signaling between 
epithelial tumor cells and fibroblasts in carcinoma formation." Exp Cell Res 
264(1): 169-84. 
25. Elzer, K. L., D. A. Heitzman, et al. (2008). "Differential effects of serine 
proteases on the migration of normal and tumor cells: implications for tumor 
microenvironment." Integr Cancer Ther 7(4): 282-94. 
26. Frade, R., N. Rousselet, et al. (2008). "Intratumoral gene delivery of anti-
cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor 
progression induced by human melanoma cells." Cancer Gene Ther 15(9): 591-
604. 
27. Gorsch, S. M., V. A. Memoli, et al. (1992). "Immunohistochemical staining for 
transforming growth factor beta 1 associates with disease progression in 
human breast cancer." Cancer Res 52(24): 6949-52. 
28. Gossen, M. and H. Bujard (1992). "Tight control of gene expression in 
mammalian cells by tetracycline-responsive promoters." Proc Natl Acad Sci U 
S A 89(12): 5547-51. 
29. Gossen, M. and H. Bujard (1995). "Efficacy of tetracycline-controlled gene 
expression is influenced by cell type: commentary." Biotechniques 19(2): 213-6; 
discussion 216-7. 
30. Grunert, S., M. Jechlinger, et al. (2003). "Diverse cellular and molecular 
mechanisms contribute to epithelial plasticity and metastasis." Nat Rev Mol 
Cell Biol 4(8): 657-65. 
31. Hanahan, D. and R. A. Weinberg (2000). "The hallmarks of cancer." Cell 100(1): 
57-70. 
32. Hochedlinger, K., Y. Yamada, et al. (2005). "Ectopic expression of Oct-4 blocks 
progenitor-cell differentiation and causes dysplasia in epithelial tissues." Cell 
121(3): 465-77. 
33. Huber, M. A., N. Azoitei, et al. (2004). "NF-kappaB is essential for epithelial-
mesenchymal transition and metastasis in a model of breast cancer 
progression." J Clin Invest 114(4): 569-81. 
34. Huber, M. A., N. Kraut, et al. (2005). "Molecular requirements for epithelial-
mesenchymal transition during tumor progression." Curr Opin Cell Biol 17(5): 
548-58. 
 93 
35. Jaisser, F. (2000). "Inducible gene expression and gene modification in 
transgenic mice." J Am Soc Nephrol 11 Suppl 16: S95-S100. 
36. Janda, E., K. Lehmann, et al. (2002). "Ras and TGF[beta] cooperatively regulate 
epithelial cell plasticity and metastasis: dissection of Ras signaling pathways." 
J Cell Biol 156(2): 299-313.  
37. Jechlinger, M., A. Sommer, et al. (2006). "Autocrine PDGFR signaling 
promotes mammary cancer metastasis." J Clin Invest 116(6): 1561-70. 
38. Jechlinger, M., S. Grunert, et al. (2002). "Mechanisms in epithelial plasticity 
and metastasis: insights from 3D cultures and expression profiling." J 
Mammary Gland Biol Neoplasia 7(4): 415-32. 
39. Jechlinger, M., S. Grunert, et al. (2003). "Expression profiling of epithelial 
plasticity in tumor progression." Oncogene 22(46): 7155-69.  
40. Jedeszko, C. and B. F. Sloane (2004). "Cysteine cathepsins in human cancer." 
Biol Chem 385(11): 1017-27. 
41. Karnoub, A. E. and R. A. Weinberg (2008). "Ras oncogenes: split personalities." 
Nat Rev Mol Cell Biol 9(7): 517-31. 
42. Kirstein, J. M., K. C. Graham, et al. (2009). "Effect of anti-fibrinolytic therapy 
on experimental melanoma metastasis." Clin Exp Metastasis 26(2): 121-31. 
43. Liapis, H., A. Flath, et al. (1996). "Integrin alpha V beta 3 expression by bone-
residing breast cancer metastases." Diagn Mol Pathol 5(2): 127-35. 
44. Liotta, L. A. and E. C. Kohn (2001). "The microenvironment of the tumour-host 
interface." Nature 411(6835): 375-9. 
45. Massague, J. (1998). "TGF-beta signal transduction." Annu Rev Biochem 67: 
753-91. 
46. McCawley, L. J. and L. M. Matrisian (2001). "Matrix metalloproteinases: 
they're not just for matrix anymore!" Curr Opin Cell Biol 13(5): 534-40. 
47. Mignatti, P. and D. B. Rifkin (1993). "Biology and biochemistry of proteinases 
in tumor invasion." Physiol Rev 73(1): 161-95. 
48. Mikulits, W., B. Pradet-Balade, et al. (2000). "Isolation of translationally 
controlled mRNAs by differential screening." Faseb J 14(11): 1641-52. 
49. Mueller, M. M. and N. E. Fusenig (2004). "Friends or foes - bipolar effects of 
the tumour stroma in cancer." Nat Rev Cancer 4(11): 839-49. 
50. Oft, M., J. Peli, et al. (1996). "TGF-beta1 and Ha-Ras collaborate in modulating 
the phenotypic plasticity and invasiveness of epithelial tumor cells." Genes 
Dev 10(19): 2462-77. 
51. Oft, M., K. H. Heider, et al. (1998). "TGFbeta signaling is necessary for 
carcinoma cell invasiveness and metastasis." Curr Biol 8(23): 1243-52. 
52. O. De Wever, M. Mareel, et at. (2003). “Role of tissue stroma in cancer cell invasion.“ 
J Pathol. 200(4):429-4 
53. Pendurthi, U. R., M. Ngyuen, et al. (2002). "Plasmin induces Cyr61 gene 
expression in fibroblasts via protease-activated receptor-1 and p44/42 
mitogen-activated protein kinase-dependent signaling pathway." Arterioscler 
Thromb Vasc Biol 22(9): 1421-6. 
54. Pilipenko, V. V., A. Reece, et al. (2004). "Genomic organization and expression 
analysis of the murine Fam3c gene." Gene 335: 159-68. 
 94 
55. Pollard, J. W. (2004). "Tumour-educated macrophages promote tumour 
progression and metastasis." Nat Rev Cancer 4(1): 71-8. 
56. Portella, G., S. A. Cumming, et al. (1998). "Transforming growth factor beta is 
essential for spindle cell conversion of mouse skin carcinoma in vivo: 
implications for tumor invasion." Cell Growth Differ 9(5): 393-404. 
57. Rajalingam, K., R. Schreck, et al. (2007). "Ras oncogenes and their downstream 
targets." Biochim Biophys Acta 1773(8): 1177-95. 
58. Rakic, J. M., C. Maillard, et al. (2003). "Role of plasminogen activator-plasmin 
system in tumor angiogenesis." Cell Mol Life Sci 60(3): 463-73. 
59. Repasky, G. A., E. J. Chenette, et al. (2004). "Renewing the conspiracy theory 
debate: does Raf function alone to mediate Ras oncogenesis?" Trends Cell Biol 
14(11): 639-47. 
60. Schubbert, S., K. Shannon, et al. (2007). "Hyperactive Ras in developmental 
disorders and cancer." Nat Rev Cancer 7(4): 295-308. 
61. Smith, H. W. and C. J. Marshall "Regulation of cell signalling by uPAR." Nat 
Rev Mol Cell Biol 11(1): 23-36. 
62. Sporn, M. B. (1996). "The war on cancer." Lancet 347(9012): 1377-81. 
63. Thiery, J. P. (2003). "Epithelial-mesenchymal transitions in development and 
pathologies." Curr Opin Cell Biol 15(6): 740-6. 
64. Thiery, J. P. and J. P. Sleeman (2006). "Complex networks orchestrate 
epithelial-mesenchymal transitions." Nat Rev Mol Cell Biol 7(2): 131-42. 
65. Turner, G. A. and L. Weiss (1981). "Analysis of aprotinin-induced 
enhancement of metastasis of Lewis lung tumors in mice." Cancer Res 41(7): 
2576-80. 
66. Urlinger, S., U. Baron, et al. (2000). "Exploring the sequence space for 
tetracycline-dependent transcriptional activators: novel mutations yield 
expanded range and sensitivity." Proc Natl Acad Sci U S A 97(14): 7963-8. 
67. Waerner, T., M. Alacakaptan, et al. (2006). "ILEI: a cytokine essential for EMT, 
tumor formation, and late events in metastasis in epithelial cells." Cancer Cell 
10(3): 227-39. 
68. Wakefield, L. M. and A. B. Roberts (2002). "TGF-beta signaling: positive and 
negative effects on tumorigenesis." Curr Opin Genet Dev 12(1): 22-9. 
69. Webb, C. P., L. Van Aelst, et al. (1998). "Signaling pathways in Ras-mediated 
tumorigenicity and metastasis." Proc Natl Acad Sci U S A 95(15): 8773-8. 
70. Welch, D. R., A. Fabra, et al. (1990). "Transforming growth factor beta 
stimulates mammary adenocarcinoma cell invasion and metastatic potential." 
Proc Natl Acad Sci U S A 87(19): 7678-82. 
71. World Health Organization "Cancer" (February 2006)  
             http://www.who.int/mediacentre/factsheets/fs297/en/. Retrieved 2007-06-25 
72. Yang, J., S. A. Mani, et al. (2004). "Twist, a master regulator of morphogenesis, 
plays an essential role in tumor metastasis." Cell 117(7): 927-39. 
73. Yin, Y. J., Z. Salah, et al. (2003). "Oncogenic transformation induces tumor 
angiogenesis: a role for PAR1 activation." Faseb J 17(2): 163-74. 
74. Zhu, Y., G. Xu, et al. (2002). "Cloning, expression, and initial characterization 
of a novel cytokine-like gene family." Genomics 80(2): 144-50. 
 
 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97 
Curriculum Vitae 
 
 
Personal Details 
 
Name :                Betül ULUCA 
 
Date of Birth :    19.06.1984  
 
Place of Birth :   Istanbul/Turkey 
 
Nationality :       Turkish 
 
 
 
Education 
 
1999-2002          Kadiköy Imam Hatip High School, Turkey  
 
2003-2004          German Preparatory Course „Universitätslehrgang- 
                           Vorstudienlehrgang“, Vienna 
 
2004-2011          Studies of Microbiology and Genetics, University of Vienna  
 
